
	



<!--
-->
<html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en"><head xmlns=""><META http-equiv="Content-Type" content="text/html; charset=utf-8"><title>A new link between the c-Abl tyrosine kinase and phosphoinositide signalling through PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 - Nature Cell Biology</title><meta name="description" content="Nature cell biology is a science journal containing cell biology articles and research papers on cell division, cell structure, animal and plant cell biology and cell cycles." />
<meta name="keywords" content="Nature cell biology, biology articles, cell signalling, cell structure biology, stem cell research, nature, stem cells, animal cells, plant cells, science fairs, cell biology, articles on biology, journal of cell biology, creative labs, science experiments, human anatomy, science news, science articles, science magazines, cell membranes, adipose tissue, science and nature, animal cell biology, microbiology, muscular physiology, molecular cell biology, biochem, molecular biology of the cell, laboratory, labs, red blood cells, female anatomy, science journals, science labs, anatomy and physiology, science and technology, apoptosis, nature magazines, molecular biology, protein synthesis, science news articles, plasma membranes, biology news, cell division, cell cycles, receptor mediated, lighting microscopy, plant cell biology." /><meta content="noarchive" name="robots"><link href="http://www.nature.com/favicon.ico" rel="shortcut icon"><link type="text/css" href="/ncb/style_older.css" rel="stylesheet"><style media="all" type="text/css">@import "/ncb/style.css";</style>
<script type="text/javascript" language="javascript"><!--
	var include = ';;;;';
	var adinf = "lg=no;";

	if(include != ";;;;")
	{
		adinf = include;
	}

	var time = new Date();
	ordval= (time.getTime());

//-->

var thisIssue = '/ncb/journal/v5/n4';




// provides cross-browser functionality
//======================================
function getObject(name) {
  if(document.getElementById) return document.getElementById(name);
  else if(document.all) return document.all[name];
  else return null;
}

function getIssueText(){
	if (isCurrent()) {
		return 'Current issue';
	} else {
		return 'Archive';
	}
}

function getIssueBreadcrumbText(){
	if (isCurrent()) {
		return 'Current issue';
	} else {
		return 'Table of Contents';
	}
}

function setTitleImg(){
	var titleImg = getObject('titleImg');
	if (titleImg){
		titleImg.alt = getIssueText();
	}
}

</script><script src="/mailafriend/mailafriend.js" language="javascript" type="text/javascript"></script><script LANGUAGE="JavaScript">
var currentIssue = '/ncb/journal/v6/n8';

function isCurrent(){

	//check for archive content
	if (currentIssue == thisIssue){
		return true;
	} else {
		return false;
	}
}
</script></head><body marginheight="0" marginwidth="0" topmargin="0" leftmargin="0" text="#000000" bgcolor="#FFFFFF"><a name="top"/><!-- start npg global nav -->
<table width="100%" border="0" cellspacing="0" cellpadding="0">
<tr> 
<td align="center" bgcolor="#CCCCCC"> 
<table width="760" border="0" cellspacing="0" cellpadding="0">
<tr> 
<td width="34" height="37"><a href="http://npg.nature.com/npg/servlet/Content?data=xml/02_welcome.xml&amp;style=xml/02_welcome.xsl"><img src="/includes/rj_globnavimages/npg_header_logo.gif" width="26" height="26" alt="Nature Publishing Group, publisher of Nature, and other science journals and reference works" border="0" /></a></td>
<td width="7" align="left"><img src="/includes/rj_globnavimages/global_divider.gif" width="2" height="13" alt="" /></td>
<td align="center"><a href="http://www.nature.com" class="topnav">NATURE.COM</a></td>
<td width="14" align="center"><img src="/includes/rj_globnavimages/global_divider.gif" width="2" height="13" alt="" /></td>
<td align="center"><a href="/news/" class="topnav">NEWS@NATURE.COM</a></td>
<td width="14" align="center"><img src="/includes/rj_globnavimages/global_divider.gif" width="2" height="13" alt="" /></td>
<td align="center"><a href="/naturejobs/" class="topnav">NATUREJOBS</a></td>
<td width="14" align="center"><img src="/includes/rj_globnavimages/global_divider.gif" width="2" height="13" alt="" /></td>
<td align="center"><a href="/nature-events/" class="topnav">NATUREEVENTS</a></td>
<td width="14" align="center"><img src="/includes/rj_globnavimages/global_divider.gif" width="2" height="13" alt="" /></td>
<td align="center"><a href="http://npg.nature.com/npg/servlet/Content?data=xml/02_welcome.xml&amp;style=xml/02_welcome.xsl" class="topnav">ABOUT&#160;NPG</a></td>
<td width="14" align="center"><img src="/includes/rj_globnavimages/global_divider.gif" width="2" height="13" alt="" /></td>
<td width="6" align="center"><img src="/includes/rj_globnavimages/spacer.gif" width="6" height="13" alt="" /></td>
<td align="right"> 
<table width="192" border="0" cellspacing="0" cellpadding="0">
<tr> 
<td width="16"><a href="http://npg.nature.com/npg/servlet/Content?data=xml/02_welcome.xml&amp;style=xml/02_welcome.xsl"><img src="/includes/rj_globnavimages/help.gif" width="13" height="13" alt="help" border="0" /></a></td>
<td><a href="http://npg.nature.com/npg/servlet/Content?data=xml/08_help.xml&amp;style=xml/08_help.xsl" class="topnavsml">Help</a></td>
<td width="7" align="center"><img src="/includes/rj_globnavimages/spacer.gif" width="8" height="8" alt="" /></td>
<td width="16"><a href="/siteindex/"><img src="/includes/rj_globnavimages/siteindex.gif" width="12" height="12" border="0" alt="site index" /></a></td>
<td><a href="/siteindex/" class="topnavsml">Nature.com&#160;site&#160;index</a></td>
<td>&#160;</td>
</tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
<tr>
<td align="center" bgcolor="#000000" height="1"><img src="/includes/rj_globnavimages/spacer.gif" width="1" height="1" alt="" /></td>
</tr>
</table>
<!-- end global nav--><table cellpadding="0" cellspacing="0" border="0" width="100%"><tr><td align="center" bgcolor="#546D9F"><table cellpadding="0" cellspacing="0" border="0" width="760" bgcolor="#546D9F"><tr height="74"><td width="161" align="left"><a href="/ncb/"><img height="54" width="161" alt="Nature Cell Biology" border="0" src="/includes/rj_globnavimages/ncb_logo.gif"></a></td><td background="/includes/rj_globnavimages/ncb_bg_header.gif" width="100%" align="left"><img alt="" height="1" width="1" src="/includes/rj_globnavimages/spacer.gif"></td><td width="247" valign="bottom">	
	
<table width="247" height="100%" border="0" cellpadding="1" cellspacing="0" class="lgn_border">
<tr><td>
<table width="245" border="0" cellpadding="0" cellspacing="0" class="lgn_background">
<tr><td width="1"><img src="/images/spacer.gif" alt="" width="1" height="71" /></td>
<td>
<table width="244" border="0" cellpadding="0" cellspacing="0" class="lgn_background">
<form name="login" method="post" action="/login/login.taf?_action=form2&login_return=true&_UserReference=C0A804ED4652B6DFC7B47F52CC674111422D">
<tr height="10" valign="top">
<td width="2"><img src="/images/spacer.gif" alt="" width="2" height="10"/></td>
<td width="4"><img src="/images/spacer.gif" alt="" width="4" height="10"/></td>
<td width="91"><img src="/images/spacer.gif" alt="" width="91" height="10"/></td>
<td width="91"><img src="/images/spacer.gif" alt="" width="91" height="10"/></td>
<td width="56"><img src="/images/spacer.gif" alt="" width="56" height="10"/></td>
</tr>
			<tr valign="top" height="100%">
<td class="lgn_text" colspan="2">&nbsp;</td>
<td class="lgn_text" colspan="3">Full text access provided to:<br />
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<span class="lgn_textbig"><b>Weill Cornell Medical Library</b></span></td>
</tr>
<tr>
<td colspan="5"><img src="/images/spacer.gif" alt="" width="245" height="3"/></td>
</tr>
<tr valign="top">
<td class="lgn_text" colspan="2">&nbsp;</td>
<td class="lgn_text" colspan="3">by: <span class="lgn_textalt"><b>Weill Cornell Medical Library</b></span></td>
</tr>

	<tr height="6"><td colspan="5"><img src="/images/spacer.gif" alt="" width="244" height="6"/></td></tr>
</form>
</table>
</td></tr>
</table>
</td></tr>
</table></td><td valign="bottom"></td></tr></table><tr><td height="1" bgcolor="#000000" align="center"><img alt="" height="1" width="100%" src="/includes/rj_globnavimages/spacer.gif"></td></tr></td></tr></table><table cellpadding="0" cellspacing="0" border="0" width="100%"><tr><td height="30" valign="top" align="center"><table cellpadding="0" cellspacing="0" border="0" width="760"><tr><td height="30" width="459"><table cellpadding="0" cellspacing="0" border="0" width="459"><form target="_blank" method="post" action="/dynasearch/app/dynasearch.taf" name="f1"><tr><td height="30" width="133"><span class="search">SEARCH&nbsp;JOURNAL</span></td><td height="30" width="140"><input value="Exact" name="sp-w" type="hidden"><input value="search" name="_action" type="hidden"><input value="Any" name="sp-p" type="hidden"><input value="ncb" name="sp_k" type="hidden"><input style="margin-left:0px;margin-right:0px;font-family:verdana,arial,helvetica,sans-serif;width:140px;height:20px;" tabindex="5" size="8" name="search_fulltext" type="text"></td><td height="30" width="10"><img alt="" height="8" width="10" src="/includes/rj_globnavimages/spacer.gif"></td><td height="30" width="36"><input align="middle" alt="search Nature Cell Biology" border="0" height="19" tabindex="6" width="26" src="/includes/rj_globnavimages/ncb_searchgo.gif" name="submit" type="image"></td><td width="6"><img alt="" height="5" width="3" src="/ncb/images/arrow_blue.gif"></td><td width="134" height="30"><a target="_blank" class="adsearch" href="/dynasearch/app/dynasearch.taf?site_source=ncb">Advanced search</a></td></tr></form></table></td><td align="right" height="30" width="87"><a target="_blank" href="/registration/Modify_registration.taf?site_source=ncb"><img alt="my account" border="0" height="15" width="85" src="/includes/rj_globnavimages/myacct.gif"></a></td><td align="right" height="30" width="68"><a target="_blank" href="http://npg.nature.com/npg/servlet/Content?data=xml/08_account.xml&style=xml/08_account.xsl"><img alt="e-alerts" border="0" height="15" width="66" src="/includes/rj_globnavimages/ealert.gif"></a></td><td align="right" height="30" width="78"><a href="/registration/index.taf?site_source=ncb" target="_blank"><img alt="subscribe" border="0" height="15" width="76" src="/includes/rj_globnavimages/subscribe.gif"></a></td><td align="right" height="30" width="68"><a href="/registration/index.taf?site_source=ncb"><img alt="register" border="0" height="15" width="66" src="/includes/rj_globnavimages/register.gif"></a></td></tr><tr><td height="4" colspan="5" bgcolor="#546D9F"><img alt="" height="4" width="1" src="/images/spacer.gif"></td></tr></table></td></tr></table><table cellpadding="0" cellspacing="0" border="0" width="100%"><tr xmlns=""><td valign="top" height="22" align="center"><table cellpadding="0" cellspacing="0" border="0" width="760"><tr><td height="22" bgcolor="#DFE9FD" width="145">&nbsp;</td><td align="left" width="630" height="22" bgcolor="#DFE9FD" class="breadcrumb"><a class="breadcrumblink" href="/ncb/index.html">Journal home</a>&nbsp;&gt;
<script LANGUAGE="JavaScript">
	if (!isCurrent()){
	document.write('<a class="breadcrumblink" href="/cgi-taf/DynaPage.taf?file=/ncb/archive/index.html">Archive</a>&nbsp;&gt;');
	}
</script>
<a class="breadcrumblink" href="/cgi-taf/DynaPage.taf?file=/ncb/journal/v5/n4/index.html">
<script LANGUAGE="JavaScript">
	document.write(getIssueBreadcrumbText());
</script></a>&nbsp;&gt;&nbsp;<a class="breadcrumblink" href="/cgi-taf/DynaPage.taf?file=/ncb/journal/v5/n4/index.html#af">Article</a> &gt; Full text</td></tr></table></td></tr><tr><td align="center"><table cellpadding="0" cellspacing="0" border="0" width="760"><tr><td valign="top" width="130"><input xmlns="" value="issue" id="leftnav_type" type="hidden"><input xmlns="" value="af" id="categ" type="hidden"><input xmlns="" value="" id="arch_categ" type="hidden"><script LANGUAGE="JavaScript">
var bgColorOn = "#546D9F";
var bgColor2 = "#EAEAEA";
//var bgClassOn = "leftnavOn_bg";
var imageOn = "/includes/rj_globnavimages/nav_dots1.gif";
var imageOff = "/includes/rj_globnavimages/nav_dots2.gif";
var imageSpacer = "/includes/rj_globnavimages/spacer.gif";

var issueType = 'issue';
var archiveType = 'archive';

var children = new Array();

function addSubLevel(parent, child){
	children[parent] = child;
}

function getObjectRef(name) {
  if(document.getElementById) return document.getElementById(name);
  else if(document.all) return document.all[name];
  else return null;
}

var thisPageType = '';

function setPageType(){
	var type = getObjectRef("leftnav_type").value;
	//alert(type);

	if (type == null){
		type = '';
	}

	//check for archive content
	if (type == issueType && !isCurrent()){
		type = archiveType;
	}

	thisPageType = type;
}

function getPageType(){
	return thisPageType;
}

setPageType();

function isCurrentType(thisType){
	if (thisType == getPageType()){
		return true;
	}else{
		var isChild = false;
		if (typeof children[thisType] != "undefined"){
			var child = children[thisType];
			for (var i=0; i<child.length; i++){
				if (getPageType() == child[i]){
					isChild = true;
				}
			}
		}
		return isChild;
	}
}

function getNewSubRow(name, linkhref, text){
	return '<tr><td width="5" style="background-color:'+bgColor2+'" id="'+name+'_1"><img src="'+imageSpacer+'" width="5" height="15" alt=""></td><td style="background-color:'+bgColor2+'" id="'+name+'_2" valign="top"><img src="'+imageOff+'" id="'+name+'_image" width="5" height="7" alt="" vspace="2"></td><td style="background-color:'+bgColor2+'" id="'+name+'_3"><img src="'+imageSpacer+'" width="5" height="15" alt=""></td><td style="background-color:'+bgColor2+'" id="'+name+'_4"><a href="'+linkhref+'" class="leftnav3" id="'+name+'_link">'+text+'</a></td><td width="5" style="background-color:'+bgColor2+'" id="'+name+'_5" valign="top"><img src="'+imageSpacer+'" width="5" height="15" alt=""></td></tr>';
}

function getSubRow(newRows){
	if (newRows != ''){
		return '<img src="'+imageSpacer+'" width="5" height="1" alt=""></td></tr><tr><td height="1" colspan="3"><table width="100%" cellpadding="0" cellspacing="0" border="0">'+newRows+'</table><tr><td colspan="3" height="1"><img src="'+imageSpacer+'" width="5" height="1" alt=""></td></tr>'
	} else {
		//return '<img src="'+imageSpacer+'" width="5" height="1" alt="">';
		return '';
	}
}

function hilite(text) {
// set colors

//alert(getObjectRef(text+"_1").style.backgroundColor);
	if (getObjectRef(text+"_link") != null){

		var num = 1;
		while (getObjectRef(text+"_"+num)){
			//getObjectRef(text+"_"+num).className  = bgClassOn;
			getObjectRef(text+"_"+num).style.backgroundColor = bgColorOn;
			num++;
		}

		getObjectRef(text+"_link").className = getObjectRef(text+"_link").className+"On";
	}

	if (getObjectRef(text+"_image") != null){
		//alert(getObjectRef(text+"_image").src);
		getObjectRef(text+"_image").src = imageOn;
	}

}

</script><table cellpadding="0" cellspacing="0" border="0" width="130"><tr><td height="1" colspan="3"><img alt="" height="1" width="5" src="/images/spacer.gif"></td></tr><tr><td id="home_1" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td><td id="home_2" style="background-color:
#DFE9FD"><a class="leftnav" href="/ncb/index.html" id="home_link">Journal home</a></td><td id="home_3" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td></tr><tr><td height="1" colspan="3"></td></tr><tr><td id="aop_1" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td><td id="aop_2" style="background-color:
#DFE9FD"><a class="leftnav" href="/cgi-taf/DynaPage.taf?file=/ncb/journal/vaop/ncurrent/index.html" id="aop_link">Advance online publication</a></td><td id="aop_3" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td></tr><tr><td height="1" colspan="3"><script LANGUAGE="JavaScript">

var thisType = 'aop';

addSubLevel(thisType, new Array("About_AOP"));

var newRows = '';
if (isCurrentType(thisType) || '' == 'true'){

	
	newRows += getNewSubRow('About_AOP', '/ncb/aop/index.html', 'About AOP');
		

	if (isCurrentType(thisType) && thisType != getPageType()){
		hilite(thisType);
	}

}

document.write (getSubRow(newRows));
</script></td></tr><tr><td id="issue_1" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td><td id="issue_2" style="background-color:
#DFE9FD"><a class="leftnav" href="/cgi-taf/DynaPage.taf?file=/ncb/journal/v6/n7/index.html" id="issue_link">
Current issue
</a></td><td id="issue_3" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td></tr><tr><td height="1" colspan="3"></td></tr><tr><td id="archive_1" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td><td id="archive_2" style="background-color:
#DFE9FD"><a class="leftnav" href="/cgi-taf/DynaPage.taf?file=/ncb/archive/index.html" id="archive_link">Archive</a></td><td id="archive_3" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td></tr><tr><td height="1" colspan="3"></td></tr><tr><td id="Press_releases_1" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td><td id="Press_releases_2" style="background-color:
#DFE9FD"><a class="leftnav" href="/ncb/press_release/index.html" id="Press_releases_link">Press releases</a></td><td id="Press_releases_3" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td></tr><tr><td height="1" colspan="3"></td></tr></table>
<table cellpadding="0" cellspacing="0" border="0" width="130"><tr><td height="1" colspan="3"><img alt="" height="1" width="5" src="/includes/rj_globnavimages/spacer.gif"></td></tr><tr><td height="12" colspan="3"><img alt="" height="12" width="5" src="/includes/rj_globnavimages/spacer.gif"></td></tr><tr><td id="Supplements_1" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td><td id="Supplements_2" style="background-color:
#DFE9FD"><a class="leftnav2" href="/ncb/supplements/index.html" id="Supplements_link">Supplements</a></td><td id="Supplements_3" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td></tr><tr><td height="1" colspan="3"></td></tr><tr><td id="Web_Focuses_1" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td><td id="Web_Focuses_2" style="background-color:
#DFE9FD"><a class="leftnav2" href="/ncb/webfocus/index.html" id="Web_Focuses_link">Focuses</a></td><td id="Web_Focuses_3" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td></tr><tr><td height="1" colspan="3"></td></tr><tr><td id="Cell_of_the_month_1" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td><td id="Cell_of_the_month_2" style="background-color:
#DFE9FD"><a class="leftnav2" href="/ncb/image/index.html" id="Cell_of_the_month_link">Cell of the month</a></td><td id="Cell_of_the_month_3" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td></tr><tr><td height="1" colspan="3"></td></tr></table>
<table cellpadding="0" cellspacing="0" border="0" width="130"><tr><td height="12" colspan="3"><img alt="" height="12" width="5" src="/includes/rj_globnavimages/spacer.gif"></td></tr><tr><td id="For_authors_1" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td><td id="For_authors_2" style="background-color:
#DFE9FD"><a class="leftnav2" href="/ncb/authors/index.html" id="For_authors_link">For authors</a></td><td id="For_authors_3" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td></tr><tr><td height="1" colspan="3"><script LANGUAGE="JavaScript">

var thisType = 'For_authors';

addSubLevel(thisType, new Array("How_to_submit","Content_types","Editorial_process"));

var newRows = '';
if (isCurrentType(thisType) || '' == 'true'){

	
	newRows += getNewSubRow('How_to_submit', '/ncb/authors/submit/index.html', 'How to submit');
	
	newRows += getNewSubRow('Content_types', '/ncb/authors/article_types/index.html', 'Content types');
	
	newRows += getNewSubRow('Editorial_process', '/ncb/authors/ed_process/index.html', 'Editorial process');
		

	if (isCurrentType(thisType) && thisType != getPageType()){
		hilite(thisType);
	}

}

document.write (getSubRow(newRows));
</script></td></tr><tr><td id="Online submission_1" style="background-color:#DFE9FD" colspan="3"><table cellpadding="0" cellspacing="0" border="0" width="130"><tr><td height="20"><img id="Online_submission_navimage" alt="Online submission" border="0" align="absmiddle" src="/includes/rj_globnavimages/ncb_icon_onlinesub.gif"></td><td><a class="leftnav2" href="http://mts-ncb.nature.com" target="_blank" id="Online_submission_link">Online submission</a></td></tr></table></td></tr><tr><td height="1" colspan="3"></td></tr><tr><td id="Permissions_1" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td><td id="Permissions_2" style="background-color:
#DFE9FD"><a class="leftnav2" href="http://npg.nature.com/npg/servlet/Content?data=xml/01_reprints.xml&amp;style=xml/01_reprints.xsl" target="_blank" id="Permissions_link">Permissions</a></td><td id="Permissions_3" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td></tr><tr><td height="1" colspan="3"></td></tr><tr><td height="12" colspan="3"><img alt="" height="12" width="5" src="/images/spacer.gif"></td></tr><tr><td id="For_referees_1" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td><td id="For_referees_2" style="background-color:
#DFE9FD"><a class="leftnav2" href="/ncb/referees/index.html" id="For_referees_link">For referees</a></td><td id="For_referees_3" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td></tr><tr><td height="1" colspan="3"></td></tr><tr><td height="12" colspan="3"><img alt="" height="12" width="5" src="/images/spacer.gif"></td></tr><tr><td id="sample_1" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td><td id="sample_2" style="background-color:
#DFE9FD"><a class="leftnav2" href="/cgi-taf/DynaPage.taf?file=/ncb/journal/v6/n1/index.html" id="sample_link">Free online issue</a></td><td id="sample_3" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td></tr><tr><td height="1" colspan="3"></td></tr><tr><td height="12" colspan="3"><img alt="" height="12" width="5" src="/images/spacer.gif"></td></tr><tr><td id="About_the_journal_1" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td><td id="About_the_journal_2" style="background-color:
#DFE9FD"><a class="leftnav2" href="/ncb/about/index.html" id="About_the_journal_link">About the journal</a></td><td id="About_the_journal_3" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td></tr><tr><td height="1" colspan="3"><script LANGUAGE="JavaScript">

var thisType = 'About_the_journal';

addSubLevel(thisType, new Array("About_the_editors","Editorial_policies","Masthead"));

var newRows = '';
if (isCurrentType(thisType) || '' == 'true'){

	
	newRows += getNewSubRow('About_the_editors', '/ncb/about/about_eds/index.html', 'About the editors');
	
	newRows += getNewSubRow('Editorial_policies', '/ncb/about/ed_policies/index.html', 'Editorial policies');
	
	newRows += getNewSubRow('Masthead', '/ncb/about/masthead/index.html', 'Masthead');
		

	if (isCurrentType(thisType) && thisType != getPageType()){
		hilite(thisType);
	}

}

document.write (getSubRow(newRows));
</script></td></tr><tr><td id="Contact_the_journal_1" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td><td id="Contact_the_journal_2" style="background-color:
#DFE9FD"><a class="leftnav2" href="/ncb/contact/index.html" id="Contact_the_journal_link">Contact the journal</a></td><td id="Contact_the_journal_3" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td></tr><tr><td height="1" colspan="3"></td></tr><tr><td id="Subscribe_1" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td><td id="Subscribe_2" style="background-color:
#DFE9FD"><a class="leftnav2" href="/registration/index.taf?site_source=ncb" target="_blank" id="Subscribe_link">Subscribe</a></td><td id="Subscribe_3" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td></tr><tr><td height="1" colspan="3"></td></tr><tr><td id="Advertising_1" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td><td id="Advertising_2" style="background-color:
#DFE9FD"><a class="leftnav2" href="http://advertising.nature.com" target="_blank" id="Advertising_link">Advertising</a></td><td id="Advertising_3" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td></tr><tr><td height="1" colspan="3"></td></tr><tr><td id="Work_1" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td><td id="Work_2" style="background-color:
#DFE9FD"><a class="leftnav2" href="http://npg.nature.com/npg/forms/03_current.jsp" id="Work_link">work@npg</a></td><td id="Work_3" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td></tr><tr><td height="1" colspan="3"></td></tr><tr><td id="Reprints_1" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td><td id="Reprints_2" style="background-color:
#DFE9FD"><a class="leftnav2" href="http://www.naturereprints.com" target="_blank" id="Reprints_link">naturereprints</a></td><td id="Reprints_3" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td></tr><tr><td height="1" colspan="3"></td></tr><tr><td id="About_this_site_1" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td><td id="About_this_site_2" style="background-color:
#DFE9FD"><a class="leftnav2" href="/ncb/site/index.html" id="About_this_site_link">About this site</a></td><td id="About_this_site_3" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td></tr><tr><td height="1" colspan="3"></td></tr><tr><td height="12" colspan="3"><img alt="" height="12" width="5" src="/images/spacer.gif"></td></tr><tr><td id="For_librarians_1" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td><td id="For_librarians_2" style="background-color:
#DFE9FD"><a class="leftnav2" href="http://npg.nature.com/npg/servlet/Content?data=xml/07_home.xml&amp;style=xml/07_home.xsl" target="_blank" id="For_librarians_link">For librarians</a></td><td id="For_librarians_3" width="5" style="background-color:
#DFE9FD"><img alt="" height="20" width="5" src="/includes/rj_globnavimages/spacer.gif"></td></tr><tr><td height="1" colspan="3"></td></tr></table>
<script LANGUAGE="JavaScript">
	hilite(getPageType());
</script></td><td width="15"><img alt="" height="1" width="15" src="/images/spacer.gif"/></td><td width="470" valign="top"><table cellpadding="0" cellspacing="0" border="0" width="470"><tr xmlns=""><td valign="top" height="21"><img alt="" height="21" width="1" src="/images/spacer.gif"></td></tr><tr xmlns=""><td valign="top" height="22"><span class="categ_large">Article</span></td></tr><tr xmlns=""><td><img alt="" height="1" width="470" src="/ncb/images/spacer_grey.gif"></td></tr><tr xmlns=""><td height="14"><img alt="" height="14" width="1" src="/images/spacer.gif"></td></tr><tr><td><span xmlns="" class="blacksml"><i>Nature Cell Biology</i>
&nbsp;<b>5</b>, 309 - 319 (2003)
 <br>Published online: 24&nbsp;March&nbsp;2003;  | doi:10.1038/ncb949
</span><h2 xmlns="">A new link between the c-Abl tyrosine kinase and phosphoinositide signalling through PLC-<img border=0 src="/__chars/gamma/black/bold/big/glyph.gif" align="middle" alt="big gamma">1</h2><span xmlns="" class="author">Rina Plattner<sup>1</sup>, Brenda J. Irvin<sup>1,&nbsp;</sup><sup>5</sup>, Shuling Guo<sup>1,&nbsp;</sup><sup>6</sup>, Kevin Blackburn<sup>2</sup>, Andrius Kazlauskas<sup>3</sup>, Robert T. Abraham<sup>1,&nbsp;</sup><sup>7</sup>, John D. York<sup>1,&nbsp;</sup><sup>4</sup>
&amp;&nbsp;Ann Marie Pendergast<sup>1</sup><p class="blacksml"><sup>1</sup>&nbsp;Department of Pharmacology and Cancer Biology Duke University Medical Center Durham, NC 27710, USA</p><p class="blacksml"><sup>2</sup>&nbsp;Proteomic Technologies GlaxoSmithKline Research Triangle Park, NC 27709, USA</p><p class="blacksml"><sup>3</sup>&nbsp;Schepens Eye Research Institute Harvard Medical School Boston, MA 02114, USA</p><p class="blacksml"><sup>4</sup>&nbsp;Howard Hughes Medical Institute Duke University Medical Center Durham, NC 27710, USA</p><p class="blacksml"><sup>5</sup>&nbsp;Present Address: Department of Biochemistry Vanderbilt University Nashville, TN 37232, USA</p><p class="blacksml"><sup>6</sup>&nbsp;Present Address: Howard Hughes Medical Institute Dept. of Microbiology, Immunology, &amp; Molecular Genetics University of California at Los Angeles, CA 90095, USA</p><p class="blacksml"><sup>7</sup>&nbsp;Present Address: The Burnham Institute 10901 North Torrey Pines Road La Jolla, CA 92037, USA</p><span class="blacksml">
Correspondence should be addressed to Ann Marie Pendergast <a href="mailto:pende014@mc.duke.edu">pende014@mc.duke.edu</a></span></span><table xmlns="" cellpadding="0" cellspacing="0" border="0" width="450"><tr><td height="20"><img alt="" height="20" width="1" src="/images/spacer.gif"></td></tr><tr><td height="1"><img alt="" height="1" width="450" src="/ncb/images/spacer_grey.gif"></td></tr><tr><td height="20"><img alt="" height="20" width="1" src="/images/spacer.gif"></td></tr></table><a xmlns="" name="abstract"></a><span xmlns="" class="articletext"><b>The c-Abl tyrosine (Tyr) kinase is activated after platelet-derived-growth factor receptor (PDGFR) stimulation in a manner that is partially dependent on Src kinase activity. However, the activity of Src kinases alone is not sufficient for activation of c-Abl by PDGFR. Here we show that functional phospholipase C-<img border=0 src="/__chars/gamma/black/bold/base/glyph.gif" align="middle" alt="bold gamma">1 (PLC-<img border=0 src="/__chars/gamma/black/bold/base/glyph.gif" align="middle" alt="bold gamma">1) is required for c-Abl activation by PDGFR. Decreasing cellular levels of phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P<sub>2</sub>) by PLC-<img border=0 src="/__chars/gamma/black/bold/base/glyph.gif" align="middle" alt="bold gamma">1-mediated hydrolysis or dephosphorylation by an inositol polyphosphate 5-phosphatase (Inp54) results in increased Abl kinase activity. c-Abl functions downstream of PLC-<img border=0 src="/__chars/gamma/black/bold/base/glyph.gif" align="middle" alt="bold gamma">1, as expression of kinase-inactive c-Abl blocks PLC-<img border=0 src="/__chars/gamma/black/bold/base/glyph.gif" align="middle" alt="bold gamma">1-induced chemotaxis towards PDGF-BB. PLC-<img border=0 src="/__chars/gamma/black/bold/base/glyph.gif" align="middle" alt="bold gamma">1 and c-Abl form a complex in cells that is enhanced by PDGF stimulation. After activation, c-Abl phosphorylates PLC-<img border=0 src="/__chars/gamma/black/bold/base/glyph.gif" align="middle" alt="bold gamma">1 and negatively modulates its function <i>in vivo</i>. These findings uncover a newly discovered functional interdependence between non-receptor Tyr kinase and lipid signalling pathways.</b></span><table xmlns="" cellpadding="0" cellspacing="0" border="0" width="470"><tr><td height="20"><img alt="" height="20" width="1" src="/images/spacer.gif"></td></tr><tr><td height="1"><img alt="" height="1" width="470" src="/ncb/images/spacer_grey.gif"></td></tr><tr><td height="20"><img alt="" height="20" width="1" src="/images/spacer.gif"></td></tr></table><span xmlns="" class="articletext">The activation mechanism of the c-Abl Tyr kinase has remained elusive, despite its identification more than 20 years ago. c-Abl is located in multiple cellular compartments and its activity is modulated by various stimuli<sup><a href="#B1">1, 
</a></sup><sup><a href="#B2">2, 
</a></sup><sup><a href="#B3">3</a></sup>. The membrane pool of c-Abl is activated downstream of the PDGFR in a manner partially dependent on the Src family kinases<sup><a href="#B4">4</a></sup> and c-Abl is important in membrane ruffling downstream of PDGF<sup><a href="#B4">4</a></sup>. Here, we uncover a novel component of the signal transduction pathway that results in c-Abl activation downstream of the PDGFR.</span><br xmlns=""><br xmlns=""><span xmlns="" class="articletext">Two PDGFRs (<img border=0 src="/__chars/alpha/black/med/base/glyph.gif" align="bottom" alt="alpha"> and <img border=0 src="/__chars/beta/black/med/base/glyph.gif" align="middle" alt="beta">) bind to four PDGF growth factors (A&#150;D). A major downstream effector of the activated PDGFRs is PLC<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">, and PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 is the major isoform expressed in fibroblasts<sup><a href="#B5">5</a></sup>. Activated PDGFRs phosphorylate PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1, resulting in its subsequent activation<sup><a href="#B5">5</a></sup>. Once activated, PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 hydrolyses PtdIns(4,5)P<sub>2</sub> to produce the second messengers inositol-1,4,5-trisphosphate (InsP<sub>3</sub>) and diacylglycerol (DAG). PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 contains a pleckstrin homology (PH) domain, split PH and catalytic lipase domains (X and Y), which are separated by two SH2 (Src-homology domain-2) domains (amino- and carboxy-terminal) and an SH3 domain<sup><a href="#B5">5</a></sup>. PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 is directly phosphorylated by the PDGFR at three sites (Tyr 771, Tyr 783 and Tyr 1254)<sup><a href="#B6">6</a></sup>. Phosphorylation of Tyr 783 is essential for activation of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 by PDGF<sup><a href="#B6">6</a></sup>. PtdIns(3,4,5)P<sub>3</sub>, the product of phosphatidylinositol-3 kinase (PI-(3)K activation, is required for full activation of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 in some systems<sup><a href="#B5">5</a></sup>. Phosphorylation of Tyr 771 may negatively regulate PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 (ref. <a href="#B6">6</a>) and protein kinase C (PKC) may downregulate PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 through serine phosphorylation <i>in vitro</i><sup><a href="#B7">7</a></sup>. However, the mechanisms that result in inactivation of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 <i>in vivo</i> after PDGF stimulation remain to be defined.</span><br xmlns=""><br xmlns=""><span xmlns="" class="articletext">PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma"> is important in directed cell migration<sup><a href="#B8">8</a></sup> and wound-healing<sup><a href="#B9">9</a></sup>, as well as in neurite outgrowth<sup><a href="#B10">10</a></sup>, membrane ruffling<sup><a href="#B11">11</a></sup>, macropinocytosis<sup><a href="#B12">12</a></sup> and possibly mitogenesis<sup><a href="#B5">5</a></sup>. The substrate and products of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 are critically important in cytoskeletal reorganization, cell adhesion and migration<sup><a href="#B13">13, 
</a></sup><sup><a href="#B14">14</a></sup>. Similarly, the c-Abl Tyr kinase and the related Arg tyrosine kinase (Abl2) are linked to cytoskeletal reorganization<sup><a href="#B4">4, 
</a></sup><sup><a href="#B15">15, 
</a></sup><sup><a href="#B16">16, 
</a></sup><sup><a href="#B17">17</a></sup>, cell migration (wound healing, chemotaxis)<sup><a href="#B18">18, 
</a></sup><sup><a href="#B19">19</a></sup> and neurite outgrowth<sup><a href="#B20">20, 
</a></sup><sup><a href="#B21">21</a></sup>. Similar to PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1, c-Abl localizes to membrane ruffles and translocates to the plasma membrane after growth factor stimulation<sup><a href="#B19">19, 
</a></sup><sup><a href="#B22">22</a></sup>. Here, we uncover a bidirectional link between PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 and the c-Abl Tyr kinase.</span><br xmlns=""><br xmlns=""><a xmlns="" name="Results"></a><span xmlns="" class="heading3">Results</span><br xmlns=""><a xmlns="" name="PLC-|[gamma]|1 activity is required for activation of c-Abl by PDGF."></a><span xmlns="" class="articletext"><b>PLC-<img border=0 src="/__chars/gamma/black/bold/base/glyph.gif" align="middle" alt="bold gamma">1 activity is required for activation of c-Abl by PDGF.</b></span><br xmlns=""><span xmlns="" class="articletext">To determine the mechanism of c-Abl activation by PDGF, we used Ph cells (a murine 3T3 line carrying a deletion of the endogenous PDGFR-<img border=0 src="/__chars/alpha/black/med/base/glyph.gif" align="bottom" alt="alpha">) to express various forms of a chimeric receptor containing the extracellular domain of the PDGFR-<img border=0 src="/__chars/alpha/black/med/base/glyph.gif" align="bottom" alt="alpha"> and the intracellular domain of the PDGFR-<img border=0 src="/__chars/beta/black/med/base/glyph.gif" align="middle" alt="beta">. These chimeric receptors are activated by PDGF-AA, but stimulate PDGFR-<img border=0 src="/__chars/beta/black/med/base/glyph.gif" align="middle" alt="beta"> signalling events<sup><a href="#B23">23</a></sup>. Ph cells expressing wild-type, kinase-dead and receptors with various Tyr to Phe mutations (which disrupt the binding of specific SH2-containing proteins in the intracellular domain) were generated<sup><a href="#B23">23</a></sup>. F72/74 lacks the Src-binding sites, whereas the F5 mutant retains the Src-binding sites but lacks the binding sites for SHP-2, PI(3)K, Ras-GTPase-activating proteins (Ras-GAP) and PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 (<a href="#f1">Fig. 1a</a>). After serum withdrawal, cells were stimulated with PDGF-AA and endogenous c-Abl activity was measured by an <i>in vitro</i> kinase assay. c-Abl was activated in cells expressing the wild-type PDGFR, but not in cells expressing a kinase-dead version (<a href="#f1">Fig. 1b</a>). As reported previously, mutation of the Src-binding sites (F72/74) reduced activation of c-Abl by PDGF (<a href="#f1">Fig. 1b</a>)<sup><a href="#B4">4</a></sup>. Unexpectedly, activation of c-Abl by PDGF was completely abolished in cells expressing the F5 receptor which retains the Src-binding sites (<a href="#f1">Fig. 1b</a>). These findings indicate that Src kinase activity is necessary, but not sufficient, for full activation of c-Abl by PDGF and that at least one of the molecules unable to bind to this receptor (SHP-2, PI(3)K, Ras-GAP or PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1) is required for activation of c-Abl.</span><br xmlns=""><br xmlns=""><a xmlns="" name="f1"></a><table xmlns="" cellpadding="10" cellspacing="0" border="0" width="470"><tr><td><img alt="" height="2" width="1" src="/images/spacer.gif"></td></tr><tr><td bgcolor="#DFE9FD"><table cellpadding="0" cellspacing="0" border="0" width="430"><tr><td class="articletext" colspan="2"><b><a onclick="window.open('/ncb/journal/v5/n4/fig_tab/ncb949_F1.html','Figure_window','toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=yes,copyhistory=yes,width=617,top=20,left=20');return false;" href="/ncb/journal/v5/n4/fig_tab/ncb949_F1.html">Figure&nbsp;1.</a>&nbsp;c-Abl activation by PDGF is dependent on PLC-<img border=0 src="/__chars/gamma/black/bold/base/glyph.gif" align="middle" alt="bold gamma">1 activity.</b></td></tr><tr><td height="15"><img alt="" height="1" width="160" src="/images/spacer.gif"></td><td height="15"><img alt="" height="1" width="270" src="/images/spacer.gif"></td></tr><tr><td width="160" valign="top"><a onclick="window.open('/ncb/journal/v5/n4/fig_tab/ncb949_F1.html','Figure_window','toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=yes,copyhistory=yes,width=617,top=20,left=20');return false;" href="/ncb/journal/v5/n4/fig_tab/ncb949_F1.html"><img border="0" alt="Figure&nbsp;1 thumbnail" src="/ncb/journal/v5/n4/thumbs/ncb949-f1.jpg"></a></td><td class="blacksml" width="270" valign="top"><p class="blacksml"><b>a</b>, Schematic diagram of wild-type and mutant chimeric <img border=0 src="/__chars/alpha/black/med/base/glyph.gif" align="bottom" alt="alpha">/<img border=0 src="/__chars/beta/black/med/base/glyph.gif" align="middle" alt="beta"> PDGFR intracellular domains. P denotes phosphotyrosine and filled squares denote Tyr that have been mutated to Phe (F). Top: point mutations. Bottom: add-back mutants contain Phe in place of Tyr at the five sites indicated (F5), and have single add-back phosphotyrosines. <b>b</b>, c-Abl kinase activity after PDGF stimulation in Ph cells expressing chimeric <img border=0 src="/__chars/alpha/black/med/base/glyph.gif" align="bottom" alt="alpha">/<img border=0 src="/__chars/beta/black/med/base/glyph.gif" align="middle" alt="beta"> PDGFRs. c-Abl protein was immunoprecipitated with Pex4 antibody, and immunoprecipitates were assayed for c-Abl kinase activity using GST&#150;Crk as a substrate. KD denotes a kinase-dead receptor. The average fold activation from three experiments was 3.5 <img border=0 src="/__chars/plus/special/plusmn/black/med/base/glyph.gif" align="bottom"> 0.4, 1.9 <img border=0 src="/__chars/plus/special/plusmn/black/med/base/glyph.gif" align="bottom"> 0.6, and 2.5 <img border=0 src="/__chars/plus/special/plusmn/black/med/base/glyph.gif" align="bottom"> 0.1 fold for cells expressing wild-type, F72/74 or Y1021 receptors, respectively. <b>c</b>, c-Abl kinase activity in Ph cells expressing PDGFRs lacking the PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1-binding site (F1021) alone or lacking both the PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 and Src-binding sites (F72/74/1021). The average activation of c-Abl from three independent experiments was 3.1 <img border=0 src="/__chars/plus/special/plusmn/black/med/base/glyph.gif" align="bottom"> 0.5, 1.7 <img border=0 src="/__chars/plus/special/plusmn/black/med/base/glyph.gif" align="bottom"> 0.1 and 1.4 <img border=0 src="/__chars/plus/special/plusmn/black/med/base/glyph.gif" align="bottom"> 0.3 fold in wild-type, F1021 or F72/74/1021-expressing cells, respectively. <b>d</b>, Top: Ph cells expressing a wild-type chimeric receptor were serum-starved, treated for 10 min with U-73122, its inactive analogue U-73343, or vehicle (DMSO) at the indicated concentrations, and stimulated with PDGF. The average fold activation of c-Abl in three independent experiments was 2.4 <img border=0 src="/__chars/plus/special/plusmn/black/med/base/glyph.gif" align="bottom"> 0.2 or 1.3 <img border=0 src="/__chars/plus/special/plusmn/black/med/base/glyph.gif" align="bottom"> 0.1 fold after pretreatment with DMSO or U-73122, respectively. U-73122, U-73343, or vehicle were incubated in the c-Abl <i>in vitro</i> kinase assay at the indicated concentrations (bottom). <b>e</b>, c-Abl activity in PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1-null mouse embryo fibroblasts infected with vector (Migr1), or with PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 (Migr1&#150;PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1). c-Abl was immunoprecipitated with AB-3 antibody. Average c-Abl activation in three experiments was 1.3 <img border=0 src="/__chars/plus/special/plusmn/black/med/base/glyph.gif" align="bottom"> 0.1 and 1.4 <img border=0 src="/__chars/plus/special/plusmn/black/med/base/glyph.gif" align="bottom"> 0.2 fold in cells expressing Migr1 5 and 10 min after PDGF stimulation respectively, whereas in cells expressing Migr1&#150;PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1, c-Abl was activated 2.2 <img border=0 src="/__chars/plus/special/plusmn/black/med/base/glyph.gif" align="bottom"> 0.4 and 2.0 <img border=0 src="/__chars/plus/special/plusmn/black/med/base/glyph.gif" align="bottom"> 0.1 fold at the same times. <b>f</b>, NIH3T3 cells were infected with retroviruses containing either vector (pBabe), PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 wild-type, or PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 dominant-negative mutants, PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1<sup>Y783F</sup> and pBabe&#150;PLC-LI (lipase-inactive). Cell lysates were then analysed for c-Abl kinase activity using K12 antibody. The average activation in the three experiments was 2.6 <img border=0 src="/__chars/plus/special/plusmn/black/med/base/glyph.gif" align="bottom"> 0.9, 4.2 <img border=0 src="/__chars/plus/special/plusmn/black/med/base/glyph.gif" align="bottom"> 0.8, 1.3 <img border=0 src="/__chars/plus/special/plusmn/black/med/base/glyph.gif" align="bottom"> 0.0, and 1.0 <img border=0 src="/__chars/plus/special/plusmn/black/med/base/glyph.gif" align="bottom"> 0.0 fold in cells expressing vector, wild-type PLC, PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1<sup>Y783F</sup> or PLC&#150;LI respectively.</p><br><br><a onclick="window.open('/ncb/journal/v5/n4/fig_tab/ncb949_F1.html','Figure_window','toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=yes,copyhistory=yes,width=617,top=20,left=20');return false;" href="/ncb/journal/v5/n4/fig_tab/ncb949_F1.html"><img border="0" align="bottom" alt="Full Figure" height="11" width="17" src="/ncb/images/fullsize_icon.gif"></a><a class="sml" onclick="window.open('/ncb/journal/v5/n4/fig_tab/ncb949_F1.html','Figure_window','toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=yes,copyhistory=yes,width=617,top=20,left=20');return false;" href="/ncb/journal/v5/n4/fig_tab/ncb949_F1.html">Full Figure and legend (103K)</a></td></tr></table></td></tr><tr><td><img alt="" height="2" width="1" src="/images/spacer.gif"></td></tr></table><span xmlns="" class="articletext">To identify the molecules involved in c-Abl activation, we used a series of receptor mutants that add back each Tyr mutated on the F5 receptor (<a href="#f1">Fig. 1a</a>). Addition of Tyr 771, Y740/Y751 and Y1009 had little effect on activation of c-Abl by PDGF (<a href="#f1">Fig. 1b</a>). In contrast, addition of Tyr 1021 (which binds PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1) partially restored activation of c-Abl by PDGF (<a href="#f1">Fig. 1b</a>). To confirm that Tyr 1021 is required for c-Abl activation, Tyr 1021was mutated to Phe in the context of the wild-type and F72/74 receptors. Cells expressing the F1021 receptor displayed reduced activation of c-Abl by PDGF and cells expressing the F72/74/1021 receptor had even lower levels of c-Abl activation. This suggests that activation of c-Abl by PDGF requires both the Src and PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 binding sites (<a href="#f1">Fig. 1c</a>). The dependence of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 on PI(3)K activation<sup><a href="#B5">5</a></sup> may explain why the PDGFR Tyr 1021 add-back only partially restores c-Abl kinase activity (<a href="#f1">Fig. 1b</a>), as the PI(3)K binding sites were absent in this mutant.</span><br xmlns=""><br xmlns=""><span xmlns="" class="articletext">To test whether PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 functions upstream of c-Abl in a PDGF signalling pathway, Ph cells containing a wild-type chimeric receptor were pretreated with a pharmacological inhibitor of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma"> (U73122), its inactive analogue (U73343) or vehicle dimethyl sulphoxide (DMSO). Activation of c-Abl by PDGF was reduced in a dose-dependent manner after pretreatment with U-73122, but not with vehicle or the inactive analogue (<a href="#f1">Fig. 1d</a>, top). Activity of the c-Abl kinase was not directly affected by the addition of U73122 <i>in vitro</i> (<a href="#f1">Fig. 1d</a>, bottom), suggesting that inhibition of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 in the cell blocked the activation of c-Abl by PDGF.</span><br xmlns=""><br xmlns=""><span xmlns="" class="articletext">To test further whether PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 is required for activation of c-Abl by PDGF, we compared <i>PLC-<img border=0 src="/__chars/gamma/black/ital/base/glyph.gif" align="middle" alt="italic gamma">1<sup>-/-</sup></i> fibroblasts<sup><a href="#B24">24</a></sup> to these cells reconstituted with wild-type PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1. Activation of c-Abl in response to PDGF was reduced in <i>PLC-<img border=0 src="/__chars/gamma/black/ital/base/glyph.gif" align="middle" alt="italic gamma">1</i> null fibroblasts when compared with cells reconstituted with PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 (<a href="#f1">Fig. 1e</a>). Blocking endogenous PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 activity with the PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 dominant-negative mutants PLC-Y783F (which is not activated by PDGF; ref. <a href="#B6">6</a>) and a lipase-inactive (LI) mutant (which binds to the PDGFR and becomes Tyr phosphorylated but lacks lipase activity<sup><a href="#B25">25</a></sup>) inhibited PDGF induced c-Abl activation (<a href="#f1">Fig. 1f</a>). In contrast, expression of wild-type PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 increased the c-Abl activation by PDGF (<a href="#f1">Fig. 1f</a>). These data show that PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 activity is required for endogenous activation of c-Abl by PDGF and that its overexpression can potentiate c-Abl activation.</span><br xmlns=""><br xmlns=""><a xmlns="" name="Mechanism of c-Abl activation."></a><span xmlns="" class="articletext"><b>Mechanism of c-Abl activation.</b></span><br xmlns=""><span xmlns="" class="articletext">Activation of c-Abl downstream of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 could occur through one of two mechanisms. PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 activation produces InsP<sub>3</sub> and calcium, which could alter the activity of c-Abl. Alternatively, depletion of the PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 substrate, PtdIns(4,5)P<sub>2</sub>, may affect c-Abl activity. Neither calcium nor inositol phosphates altered the activity of c-Abl (<a href="#f2">Fig. 2b</a>; data not shown). We next tested whether depleting cellular PtdIns(4,5)P<sub>2</sub> affects c-Abl kinase activity <i>in vivo</i> by expressing a yeast Inp54 highly specific for PtdIns(4,5)P<sub>2</sub> (ref. <a href="#B26">26</a>). This phosphatase functions in mammalian cells, and a constitutively membrane-bound form produces lowered cellular levels of PtdIns(4,5)P<sub>2</sub> (ref. <a href="#B27">27</a>). We expressed the native active phosphatase, rather than the form targeted to the membrane, as the membrane-targeted form induces cell rounding whereas the native form does not alter cellular morphology. NIH3T3 cells expressing the active phosphatase had markedly elevated basal c-Abl kinase activity (over 20-fold) when compared with cells expressing the vector or a phosphatase-inactive (D280A) mutant (<a href="#f2">Fig. 2a</a>). Activity of the c-Abl kinase was stimulated by PDGF-BB in cells infected with vector or the inactive phosphatase, but in cells expressing the active phosphatase, the basal c-Abl kinase activity was significantly elevated and could not be further increased by the addition of PDGF (<a href="#f2">Fig. 2a</a>). These results suggest that PtdIns(4,5)P<sub>2</sub>, or a protein that binds to PtdIns(4,5)P<sub>2</sub>, might function to inhibit c-Abl kinase activity <i>in vivo</i>. The ability of both PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 and Inp54 expression to activate c-Abl suggests that PtdIns(4,5)P<sub>2</sub>, rather than the products of either enzymatic reaction, affects c-Abl kinase activity.</span><br xmlns=""><br xmlns=""><a xmlns="" name="f2"></a><table xmlns="" cellpadding="10" cellspacing="0" border="0" width="470"><tr><td><img alt="" height="2" width="1" src="/images/spacer.gif"></td></tr><tr><td bgcolor="#DFE9FD"><table cellpadding="0" cellspacing="0" border="0" width="430"><tr><td class="articletext" colspan="2"><b><a onclick="window.open('/ncb/journal/v5/n4/fig_tab/ncb949_F2.html','Figure_window','toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=yes,copyhistory=yes,width=617,top=20,left=20');return false;" href="/ncb/journal/v5/n4/fig_tab/ncb949_F2.html">Figure&nbsp;2.</a>&nbsp;PtdIns(4,5)P<sub>2</sub> inhibits c-Abl kinase activity.</b></td></tr><tr><td height="15"><img alt="" height="1" width="160" src="/images/spacer.gif"></td><td height="15"><img alt="" height="1" width="270" src="/images/spacer.gif"></td></tr><tr><td width="160" valign="top"><a onclick="window.open('/ncb/journal/v5/n4/fig_tab/ncb949_F2.html','Figure_window','toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=yes,copyhistory=yes,width=617,top=20,left=20');return false;" href="/ncb/journal/v5/n4/fig_tab/ncb949_F2.html"><img border="0" alt="Figure&nbsp;2 thumbnail" src="/ncb/journal/v5/n4/thumbs/ncb949-f2.jpg"></a></td><td class="blacksml" width="270" valign="top"><p class="blacksml"><b>a</b>, NIH3T3 cells were infected with retroviruses containing vector (pBabe&#150;puro), Inp54, or phosphatase-inactive mutants (D280A) (DA1, DA2), and c-Abl kinase activity was examined <i>in vitro</i> after immunoprecipitation with K12 antibody (top). The average activation of c-Abl after expression of the Inp54 was 22 <img border=0 src="/__chars/plus/special/plusmn/black/med/base/glyph.gif" align="bottom"> 0.2 fold. Expression of the active and inactive phosphatases was determined by northern blotting (right) using the entire phosphatase cDNA as a probe. <b>b</b>, An equal amount of lysate from 293T cells overexpressing c-Abl was immunoprecipitated with the K12 antibody and the immunoprecipitates were incubated with liposomes containing PIPs, and subjected to <i>in vitro</i> kinase assays. Three independent sets of liposomes were utilized (A&#150;C) using different times of sonication. Kinase reactions were carried out in the absence (left) or presence (right) of calcium chloride.</p><br><br><a onclick="window.open('/ncb/journal/v5/n4/fig_tab/ncb949_F2.html','Figure_window','toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=yes,copyhistory=yes,width=617,top=20,left=20');return false;" href="/ncb/journal/v5/n4/fig_tab/ncb949_F2.html"><img border="0" align="bottom" alt="Full Figure" height="11" width="17" src="/ncb/images/fullsize_icon.gif"></a><a class="sml" onclick="window.open('/ncb/journal/v5/n4/fig_tab/ncb949_F2.html','Figure_window','toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=yes,copyhistory=yes,width=617,top=20,left=20');return false;" href="/ncb/journal/v5/n4/fig_tab/ncb949_F2.html">Full Figure and legend (46K)</a></td></tr></table></td></tr><tr><td><img alt="" height="2" width="1" src="/images/spacer.gif"></td></tr></table><span xmlns="" class="articletext">To determine if PtdIns(4,5)P<sub>2</sub> directly binds to c-Abl, various fragments of c-Abl fused to glutathione <i>S</i>-transferase (GST) were used in a binding assay with immobilized phosphatidyl inositol lipids (PIPs). The c-Abl SH2&#150;SH1 domain bound to immobilized PtdIns(4,5)P<sub>2</sub> in the absence or presence of calcium (data not shown). In contrast, the c-Abl SH2 and SH3 domains alone did not bind to PtdIns(4,5)P<sub>2</sub> (data not shown). As PtdIns(4,5)P<sub>2</sub> was able to bind to the Abl kinase domain, we examined whether PtdIns(4,5)P<sub>2</sub> directly inhibited c-Abl kinase activity <i>in vitro</i>. In the absence of calcium, PtdIns(4,5)P<sub>2</sub> liposomes partially inhibited c-Abl kinase activity <i>in vitro</i>, whereas PtdIns(4)P had a lesser effect (<a href="#f2">Fig. 2b</a>, left). Calcium alters the specificity of lipids for kinases such as PKC<sup><a href="#B28">28</a></sup>. Therefore, we examined the effect of adding calcium to the c-Abl kinase assay in the presence and absence of phospholipids. Addition of calcium alone had no effect on the kinase activity of c-Abl (<a href="#f2">Fig. 2b</a>, right). In the presence of 400&#150;800 <img border=0 src="/__chars/mu/black/med/base/glyph.gif" align="middle" alt="mu">M calcium, PtdIns(4,5)P<sub>2</sub> markedly inhibited the activity of c-Abl kinase (<a href="#f2">Fig. 2b</a>, right) and the inhibitory effect was highly specific for PtdIns(4,5)P<sub>2</sub>, as no effect was observed for PtdIns(4)P under the same conditions. Under conditions where lower levels of calcium (2 <img border=0 src="/__chars/mu/black/med/base/glyph.gif" align="middle" alt="mu">M) were used, PtdIns(4,5)P<sub>2</sub> did not inhibit the activity of the c-Abl kinase <i>in vitro</i> (data not shown). These data suggest that PtdIns(4,5)P<sub>2</sub> may indirectly inhibit c-Abl and PtdIns(4,5)P<sub>2</sub> may recruit a molecule that inhibits activity of the c-Abl kinase <i>in vivo</i>. Alternatively, higher concentrations of calcium may be necessary to observe inhibition of the c-Abl kinase activity <i>in vitro</i>, and therefore PtdIns(4,5)P<sub>2</sub> cannot be ruled out as the inhibitor of c-Abl.</span><br xmlns=""><br xmlns=""><a xmlns="" name="c-Abl functions downstream of PLC-|[gamma]|1 in PDGF-induced chemotaxis."></a><span xmlns="" class="articletext"><b>c-Abl functions downstream of PLC-<img border=0 src="/__chars/gamma/black/bold/base/glyph.gif" align="middle" alt="bold gamma">1 in PDGF-induced chemotaxis.</b></span><br xmlns=""><span xmlns="" class="articletext">To determine whether activation of c-Abl downstream of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 after PDGF stimulation affects known PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1-mediated cellular responses, we analysed whether c-Abl is important in PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">-dependent chemotaxis towards PDGF-BB. Overexpression of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 increased chemotaxis of porcine aortic endothelial (PAE) cells expressing a PDGFR-<img border=0 src="/__chars/beta/black/med/base/glyph.gif" align="middle" alt="beta">, as previously reported<sup><a href="#B29">29</a></sup> (<a href="#f3">Fig. 3a&#150;d</a>). Expression of a kinase-inactive form of c-Abl blocked the migration induced by PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 (<a href="#f3">Fig. 3a&#150;d</a>). Expression of wild-type c-Abl had no effect on chemotaxis, whereas expression of a constitutively active form of Abl (v-Abl) potentiated PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1-mediated chemotaxis in response to PDGF (<a href="#f3">Fig. 3b, c</a>). Thus, c-Abl functions downstream of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 in the regulation of cellular migration toward PDGF.</span><br xmlns=""><br xmlns=""><a xmlns="" name="f3"></a><table xmlns="" cellpadding="10" cellspacing="0" border="0" width="470"><tr><td><img alt="" height="2" width="1" src="/images/spacer.gif"></td></tr><tr><td bgcolor="#DFE9FD"><table cellpadding="0" cellspacing="0" border="0" width="430"><tr><td class="articletext" colspan="2"><b><a onclick="window.open('/ncb/journal/v5/n4/fig_tab/ncb949_F3.html','Figure_window','toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=yes,copyhistory=yes,width=617,top=20,left=20');return false;" href="/ncb/journal/v5/n4/fig_tab/ncb949_F3.html">Figure&nbsp;3.</a>&nbsp;c-Abl and PLC-<img border=0 src="/__chars/gamma/black/bold/base/glyph.gif" align="middle" alt="bold gamma">1 function together to regulate chemotaxis.</b></td></tr><tr><td height="15"><img alt="" height="1" width="160" src="/images/spacer.gif"></td><td height="15"><img alt="" height="1" width="270" src="/images/spacer.gif"></td></tr><tr><td width="160" valign="top"><a onclick="window.open('/ncb/journal/v5/n4/fig_tab/ncb949_F3.html','Figure_window','toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=yes,copyhistory=yes,width=617,top=20,left=20');return false;" href="/ncb/journal/v5/n4/fig_tab/ncb949_F3.html"><img border="0" alt="Figure&nbsp;3 thumbnail" src="/ncb/journal/v5/n4/thumbs/ncb949-f3.jpg"></a></td><td class="blacksml" width="270" valign="top"><p class="blacksml">PAE cells were transfected with the GFP bicistronic vector, Migr1 or Migr1&#150;PLC together with the Mig-CD4 vector, or Mig&#150;CD4 expressing either wild-type c-Abl, kinase-inactive c-Abl or v-Abl. Chemotaxis towards PDGF-BB (10 or 40 ng ml<sup>-1</sup>) was measured in Transwell assays. The number of transfected cells (GFP-positive) that migrated in wells containing PDGF-BB were compared with the number of GFP-positive cells that migrated in the absence of PDGF-BB. To ascertain that an equivalent percentage of cells in each experimental condition expressed PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1, cells were plated on coverslips and counterstained with DAPI to determine GFP transfection efficiency. PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 transfection efficiency was equivalent in the absence or presence of c-Abl constructs. Expression of Abl constructs was confirmed by western blotting (data not shown). Four independent experiments <b>(a&#150;d)</b> are shown. The experiment in <b>d</b> was performed in duplicate.</p><br><br><a onclick="window.open('/ncb/journal/v5/n4/fig_tab/ncb949_F3.html','Figure_window','toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=yes,copyhistory=yes,width=617,top=20,left=20');return false;" href="/ncb/journal/v5/n4/fig_tab/ncb949_F3.html"><img border="0" align="bottom" alt="Full Figure" height="11" width="17" src="/ncb/images/fullsize_icon.gif"></a><a class="sml" onclick="window.open('/ncb/journal/v5/n4/fig_tab/ncb949_F3.html','Figure_window','toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=yes,copyhistory=yes,width=617,top=20,left=20');return false;" href="/ncb/journal/v5/n4/fig_tab/ncb949_F3.html">Full Figure and legend (45K)</a></td></tr></table></td></tr><tr><td><img alt="" height="2" width="1" src="/images/spacer.gif"></td></tr></table><a xmlns="" name="c-Abl and PLC-|[gamma]|1 interact."></a><span xmlns="" class="articletext"><b>c-Abl and PLC-<img border=0 src="/__chars/gamma/black/bold/base/glyph.gif" align="middle" alt="bold gamma">1 interact.</b></span><br xmlns=""><span xmlns="" class="articletext">As PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 is required for activation of c-Abl by PDGF, we examined whether the two proteins interact. Both the amino- and carboxy terminal SH2 domains from PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 strongly interacted with overexpressed c-Abl (<a href="#f4">Fig. 4a</a>, left). Overexpression of wild-type c-Abl to high levels (20&#150;50-fold) in 293T cells results in enhanced Tyr phosphorylation of c-Abl and activation of its kinase activity<sup><a href="#B30">30</a></sup>. Mutation of the Arg residue within the Phe-Leu-Val-Asn-Glu-Ser (FLVRES) motif in the PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 C-SH2 domain eliminated binding to c-Abl, suggesting that the interaction involves phosphotyrosine binding (<a href="#f4">Fig. 4a</a>, left). c-Abl contains SH3, SH2 and kinase (SH1) domains and the C terminus contains filament-(F) and globular-(G) actin-binding domains. The c-Abl SH2&#150;SH3 GST-fusion fragment strongly interacted with AU1-tagged PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1, whereas the SH2 domain alone showed a weaker interaction (<a href="#f4">Fig. 4a</a>, right) that was evident after longer exposure (data not shown). The SH3 domain alone did not interact and the Abl C terminus interacted weakly with overexpressed PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 (<a href="#f4">Fig. 4a</a>, right). Thus, the isolated SH2 domains of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 interact with c-Abl and the combined c-Abl SH2&#150;SH3 domains interact with PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 after overexpression in 293T cells.</span><br xmlns=""><br xmlns=""><a xmlns="" name="f4"></a><table xmlns="" cellpadding="10" cellspacing="0" border="0" width="470"><tr><td><img alt="" height="2" width="1" src="/images/spacer.gif"></td></tr><tr><td bgcolor="#DFE9FD"><table cellpadding="0" cellspacing="0" border="0" width="430"><tr><td class="articletext" colspan="2"><b><a onclick="window.open('/ncb/journal/v5/n4/fig_tab/ncb949_F4.html','Figure_window','toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=yes,copyhistory=yes,width=617,top=20,left=20');return false;" href="/ncb/journal/v5/n4/fig_tab/ncb949_F4.html">Figure&nbsp;4.</a>&nbsp;PLC-<img border=0 src="/__chars/gamma/black/bold/base/glyph.gif" align="middle" alt="bold gamma">1 and c-Abl form a complex.</b></td></tr><tr><td height="15"><img alt="" height="1" width="160" src="/images/spacer.gif"></td><td height="15"><img alt="" height="1" width="270" src="/images/spacer.gif"></td></tr><tr><td width="160" valign="top"><a onclick="window.open('/ncb/journal/v5/n4/fig_tab/ncb949_F4.html','Figure_window','toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=yes,copyhistory=yes,width=617,top=20,left=20');return false;" href="/ncb/journal/v5/n4/fig_tab/ncb949_F4.html"><img border="0" alt="Figure&nbsp;4 thumbnail" src="/ncb/journal/v5/n4/thumbs/ncb949-f4.jpg"></a></td><td class="blacksml" width="270" valign="top"><p class="blacksml"><b>a</b>, c-Abl was overexpressed in 293T cells, and 1 <img border=0 src="/__chars/mu/black/med/base/glyph.gif" align="middle" alt="mu">g of GST fusion proteins containing various domains of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 or GST alone were used in a pulldown assay (left). Coprecipitating c-Abl protein was detected by blotting with 8E9 antibody (left). AU1-tagged PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 was overexpressed in 293T cells, and GST fusions of c-Abl or GST alone were used to pull down PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 (right). Equal loading of all GST proteins was confirmed by Ponceau staining (data not shown). <b>b</b>, c-Abl lacking nuclear localization signals (1q2q3q) was expressed in NIH3T3 cells by retroviral infection. Cellular lysates were incubated with anti-c-Abl or a polyclonal control antibody, and the immunoprecipitates were analysed by blotting with anti-PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 (top). The blot was stripped and reprobed for c-Abl (bottom). Endogenous c-Abl was immunoprecipitated from NIH3T3 cells and the immunoprecipitates were blotted as above (right). <b>c</b>, GST fusion proteins containing c-Abl fragments were used to pull down endogenous PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 from starved (0) or PDGF-stimulated (5 min) NIH3T3 cells. <b>d</b>, AU1-tagged wild-type and mutant forms of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 were expressed alone or together with c-Abl in 293T cells. Lysates were incubated with anti-Abl K12 antibody (Abl) or a control polyclonal antibody (C) and the immunoprecipitates were blotted with anti-AU1 antibody (upper panel). The blot was stripped and reprobed with anti-Abl antibody (bottom). Whole cell lysates were blotted for c-Abl and PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 expression (right). N,C<sup>*</sup> is a double SH2 domain PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 mutant; LI is a lipase-inactive mutant.</p><br><br><a onclick="window.open('/ncb/journal/v5/n4/fig_tab/ncb949_F4.html','Figure_window','toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=yes,copyhistory=yes,width=617,top=20,left=20');return false;" href="/ncb/journal/v5/n4/fig_tab/ncb949_F4.html"><img border="0" align="bottom" alt="Full Figure" height="11" width="17" src="/ncb/images/fullsize_icon.gif"></a><a class="sml" onclick="window.open('/ncb/journal/v5/n4/fig_tab/ncb949_F4.html','Figure_window','toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=yes,copyhistory=yes,width=617,top=20,left=20');return false;" href="/ncb/journal/v5/n4/fig_tab/ncb949_F4.html">Full Figure and legend (63K)</a></td></tr></table></td></tr><tr><td><img alt="" height="2" width="1" src="/images/spacer.gif"></td></tr></table><span xmlns="" class="articletext">We next examined whether a c-Abl&#150;PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 complex could be detected in intact cells. A c-Abl and PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 complex was formed before and after PDGF stimulation (<a href="#f4">Fig. 4b</a>, right panel). PDGF stimulation increased the amount of c-Abl in the complex when low levels of a cytoplasmic form of c-Abl was introduced into NIH3T3 cells (<a href="#f4">Fig. 4b</a>, left). To further characterize the inducibility of the interaction, we examined the binding of various c-Abl fragments to endogenous PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 in NIH3T3 cells before and after PDGF stimulation. Both the SH2 and SH2&#150;SH3 domains of c-Abl interacted with endogenous PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1, but only after stimulation with PDGF (<a href="#f4">Fig. 4c</a>). The preformed complex identified before stimulation (<a href="#f4">Fig. 4b</a>) may represent pools of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 and c-Abl that do not localize to the plasma membrane, and therefore may not be affected by growth factor stimulation. The c-Abl SH3 and C-terminal domains did not bind to PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 in starved or PDGF-stimulated cells (<a href="#f4">Fig. 4c</a>). These results suggest that the interaction of c-Abl with the endogenous PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 protein is primarily mediated by the combined c-Abl SH3&#150;SH2 domains.</span><br xmlns=""><br xmlns=""><span xmlns="" class="articletext">Mutant or wild-type forms of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 were overexpressed with c-Abl in 293T cells to identify the PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 domains that mediate binding to c-Abl. PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 co-immunoprecipitated with c-Abl when the two proteins were overexpressed (<a href="#f4">Fig. 4d</a>, top). Mutation of the Arg in the FLVRES motifs (N,C<sup>*</sup>, where <sup>*</sup> indicates mutation) in both of the PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 SH2 domains disrupted binding to c-Abl (<a href="#f4">Fig. 4d</a>). Mutation of the N-SH2 domain alone had little effect on the co-immunoprecipitation of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 with c-Abl, whereas mutation of the C-SH2 (C<sup>*</sup>) domain greatly reduced the interaction (data not shown). Therefore, the C-SH2 domain provides a greater contribution to the binding. A lipase-inactive mutant of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 did not interact with c-Abl (<a href="#f4">Fig. 4d</a>). The lipase-inactive PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 mutant co-immunoprecipitates with the activated PDGFR to the same levels as wild-type PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1, demonstrating that the SH2 domains of the mutant are functional (data not shown). In addition, this lipase-inactive mutant retains the ability to induce DNA synthesis<sup><a href="#B25">25</a></sup>, suggesting that the protein is folded properly. These findings suggest that PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 lipase activity may be required for the interaction with c-Abl.</span><br xmlns=""><br xmlns=""><a xmlns="" name="c-Abl phosphorylates PLC-|[gamma]|1."></a><span xmlns="" class="articletext"><b>c-Abl phosphorylates PLC-<img border=0 src="/__chars/gamma/black/bold/base/glyph.gif" align="middle" alt="bold gamma">1.</b></span><br xmlns=""><span xmlns="" class="articletext">As there is an interaction between c-Abl and PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1, we examined whether PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 is a substrate for c-Abl <i>in vivo</i>. In the presence of overexpressed, activated c-Abl, PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 became heavily Tyr phosphorylated (<a href="#f5">Fig. 5a</a>, left). Tyr phosphorylation of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 was abolished when both SH2 domains of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 were mutated (<a href="#f5">Fig. 5a</a>). Mutation of the N-SH2 domain alone resulted in only a slight reduction in the level of phosphotyrosine, whereas mutation of the C-SH2 domain or the lipase domain markedly reduced phosphotyrosine levels (<a href="#f5">Fig. 5a</a>). These results are consistent with previous findings (<a href="#f4">Fig. 4d</a>, data not shown) and demonstrate that mutants of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 that cannot bind to c-Abl have reduced Abl-induced Tyr phosphorylation.</span><br xmlns=""><br xmlns=""><a xmlns="" name="f5"></a><table xmlns="" cellpadding="10" cellspacing="0" border="0" width="470"><tr><td><img alt="" height="2" width="1" src="/images/spacer.gif"></td></tr><tr><td bgcolor="#DFE9FD"><table cellpadding="0" cellspacing="0" border="0" width="430"><tr><td class="articletext" colspan="2"><b><a onclick="window.open('/ncb/journal/v5/n4/fig_tab/ncb949_F5.html','Figure_window','toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=yes,copyhistory=yes,width=617,top=20,left=20');return false;" href="/ncb/journal/v5/n4/fig_tab/ncb949_F5.html">Figure&nbsp;5.</a>&nbsp;c-Abl induces Tyr phosphorylation of PLC-<img border=0 src="/__chars/gamma/black/bold/base/glyph.gif" align="middle" alt="bold gamma">1 <i>in vivo</i>.</b></td></tr><tr><td height="15"><img alt="" height="1" width="160" src="/images/spacer.gif"></td><td height="15"><img alt="" height="1" width="270" src="/images/spacer.gif"></td></tr><tr><td width="160" valign="top"><a onclick="window.open('/ncb/journal/v5/n4/fig_tab/ncb949_F5.html','Figure_window','toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=yes,copyhistory=yes,width=617,top=20,left=20');return false;" href="/ncb/journal/v5/n4/fig_tab/ncb949_F5.html"><img border="0" alt="Figure&nbsp;5 thumbnail" src="/ncb/journal/v5/n4/thumbs/ncb949-f5.jpg"></a></td><td class="blacksml" width="270" valign="top"><p class="blacksml"><b>a</b>, c-Abl was co-expressed with wild-type or mutant PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 in 293T cells. Exogenous PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 was immunoprecipitated with <img border=0 src="/__chars/alpha/black/med/base/glyph.gif" align="bottom" alt="alpha">-AU1 antibody and the immunoprecipitates were probed with <img border=0 src="/__chars/alpha/black/med/base/glyph.gif" align="bottom" alt="alpha">-phosphotyrosine antibodies (4G10/PY99; top). The blot was stripped and reprobed for PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 (AU1; bottom). <b>b</b>, PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 was coexpressed with c-Abl in 293T cells and Tyr phosphorylation sites in the immunoprecipitated PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 were identified by mass spectrometry (top). <b>b</b>, PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 mutants were coexpressed with c-Abl in 293T cells, and PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 phosphorylation was assessed as in <b>a</b> (bottom). The blot was stripped and reprobed with AU1 (bottom). <b>c</b>, NIH3T3 cells were infected with vector (-) or c-Abl-<img border=0 src="/__chars/_delta/black/med/base/glyph.gif" align="bottom" alt="Delta">LX (+). Endogenous PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 was immunoprecipitated from starved and PDGF-stimulated cells, and the immunoprecipitates were blotted with anti-phosphotyrosine antibody (upper panel). The blot was stripped and reprobed for PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 (lower panel). <b>d</b>, Wild-type or mutant PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 was expressed in PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1-null cells by retroviral infection. Cells were starved and stimulated with PDGF, PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 was immunoprecipitated with anti-PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 antibody and the immunoprecipitates were probed with anti-phosphotyrosine antibodies (top). The blot was stripped and probed for PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 (middle). Overall Tyr phosphorylation was assessed by blotting whole cell lysates with antiphosphotyrosine antibodies (bottom).</p><br><br><a onclick="window.open('/ncb/journal/v5/n4/fig_tab/ncb949_F5.html','Figure_window','toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=yes,copyhistory=yes,width=617,top=20,left=20');return false;" href="/ncb/journal/v5/n4/fig_tab/ncb949_F5.html"><img border="0" align="bottom" alt="Full Figure" height="11" width="17" src="/ncb/images/fullsize_icon.gif"></a><a class="sml" onclick="window.open('/ncb/journal/v5/n4/fig_tab/ncb949_F5.html','Figure_window','toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=yes,copyhistory=yes,width=617,top=20,left=20');return false;" href="/ncb/journal/v5/n4/fig_tab/ncb949_F5.html">Full Figure and legend (90K)</a></td></tr></table></td></tr><tr><td><img alt="" height="2" width="1" src="/images/spacer.gif"></td></tr></table><span xmlns="" class="articletext">The PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 Tyr phosphorylation sites induced by c-Abl <i>in vivo</i> were mapped by mass spectrometry. Three PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 peptides were identified that contained phosphorylated Tyr (<a href="#f5">Fig. 5b</a>). These include a peptide containing Tyr 771 and Tyr 775, which was phosphorylated at one site, and peptides containing Tyr 572 and Tyr 1003. The c-Abl kinase phosphorylated PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 fragments fused to glutathione <i>S</i>-transferase (GST) <i>in vitro</i> (<a href="#f6">Fig. 6a</a>). The sites phosphorylated by c-Abl on the N+C-SH2&#150;SH3 and the C-SH2 fragments of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 were mapped by mass spectrometry. Tyr 771 was the most abundant (63%) <i>in vitro</i> Tyr phosphorylated site, followed by Tyr 783 (44%) and Tyr 703 (27%) (<a href="#f6">Fig. 6b</a>). In contrast to the <i>in vitro</i> results, Tyr 783 phosphorylation by c-Abl was not detected <i>in vivo</i> (<a href="#f5">Fig. 5b</a>, top). A highly sensitive targeted ion tandem mass spectra (TIMM) analysis<sup><a href="#B31">31</a></sup> demonstrated that the phosphorylated peptide containing Tyr 783 was not detected in cells co-expressing c-Abl, although the unphosphorylated peptide was easily isolated (data not shown). To test which sites identified by mass spectrometry were true c-Abl <i>in vivo</i> phosphorylation sites, we co-expressed PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 mutants containing Tyr to Phe mutations with c-Abl and their Tyr phosphorylation status was assessed after immunoprecipitation. Mutation of Tyr 1003 or Tyr 771 to Phe reduced the phosphorylation of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 by c-Abl <i>in vivo</i> (<a href="#f5">Fig. 5b</a>, bottom). Mutation of both Tyr 771 and Tyr 1003 significantly reduced the c-Abl-induced Tyr phosphorylation of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 to levels similar to that observed for the lipase-inactive mutant (<a href="#f5">Fig. 5b</a>). These findings demonstrate that c-Abl phosphorylates PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 <i>in vivo</i> predominantly at Tyr 771 and Tyr 1003.</span><br xmlns=""><br xmlns=""><a xmlns="" name="f6"></a><table xmlns="" cellpadding="10" cellspacing="0" border="0" width="470"><tr><td><img alt="" height="2" width="1" src="/images/spacer.gif"></td></tr><tr><td bgcolor="#DFE9FD"><table cellpadding="0" cellspacing="0" border="0" width="430"><tr><td class="articletext" colspan="2"><b><a onclick="window.open('/ncb/journal/v5/n4/fig_tab/ncb949_F6.html','Figure_window','toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=yes,copyhistory=yes,width=617,top=20,left=20');return false;" href="/ncb/journal/v5/n4/fig_tab/ncb949_F6.html">Figure&nbsp;6.</a>&nbsp;c-Abl phosphorylates PLC-<img border=0 src="/__chars/gamma/black/bold/base/glyph.gif" align="middle" alt="bold gamma">1 <i>in vitro</i>.</b></td></tr><tr><td height="15"><img alt="" height="1" width="160" src="/images/spacer.gif"></td><td height="15"><img alt="" height="1" width="270" src="/images/spacer.gif"></td></tr><tr><td width="160" valign="top"><a onclick="window.open('/ncb/journal/v5/n4/fig_tab/ncb949_F6.html','Figure_window','toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=yes,copyhistory=yes,width=617,top=20,left=20');return false;" href="/ncb/journal/v5/n4/fig_tab/ncb949_F6.html"><img border="0" alt="Figure&nbsp;6 thumbnail" src="/ncb/journal/v5/n4/thumbs/ncb949-f6.jpg"></a></td><td class="blacksml" width="270" valign="top"><p class="blacksml"><b>a</b>, c-Abl expressed in baculovirus-infected SF9 insect cells (left) or overexpressed in 293T cells (right) was immunoprecipitated with K12 antibody, and incubated in a kinase assay with various GST fusion proteins containing fragments of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1. GST&#150;PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">-N+C-SH2&#150;SH3 contains both SH2 domains and the SH3 domain. The amount of GST fragments used was equivalent as determined by Coomassie blue staining (data not shown). The positions of the GST fusion proteins are indicated with arrows. <b>b</b>, c-Abl expressed in 293T cells was immunoprecipitated with K12 antibody and incubated with GST&#150;PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">-N+C-SH2&#150;SH3 in a kinase assay. Kinase reactions were analysed by liquid chromatography/mass spectrometry. Tyr phosphorylated peaks are noted by the characteristic increase of 80 daltons in mass per mole of phosphate added. &#150;MET refers to species lacking the initial methionine residue. Phosphorylated Tyr residues were identified by trypsin digestion and tandem mass spectrometry of phosphopeptides.</p><br><br><a onclick="window.open('/ncb/journal/v5/n4/fig_tab/ncb949_F6.html','Figure_window','toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=yes,copyhistory=yes,width=617,top=20,left=20');return false;" href="/ncb/journal/v5/n4/fig_tab/ncb949_F6.html"><img border="0" align="bottom" alt="Full Figure" height="11" width="17" src="/ncb/images/fullsize_icon.gif"></a><a class="sml" onclick="window.open('/ncb/journal/v5/n4/fig_tab/ncb949_F6.html','Figure_window','toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=yes,copyhistory=yes,width=617,top=20,left=20');return false;" href="/ncb/journal/v5/n4/fig_tab/ncb949_F6.html">Full Figure and legend (60K)</a></td></tr></table></td></tr><tr><td><img alt="" height="2" width="1" src="/images/spacer.gif"></td></tr></table><span xmlns="" class="articletext">To determine whether c-Abl phosphorylates PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 after PDGF stimulation, we examined whether increasing kinase activity of c-Abl enhanced PDGF-induced PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 Tyr phosphorylation. NIH3T3 cells expressing a weakly-activated form of c-Abl containing a deletion of the C terminus<sup><a href="#B32">32</a></sup> (c-Abl-<img border=0 src="/__chars/_delta/black/med/base/glyph.gif" align="bottom" alt="Delta">LX) had increased phosphorylation of endogenous PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 in response to PDGF (<a href="#f5">Fig. 5c</a>). To determine whether PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 Tyr 771 and Tyr 1003 are phosphorylated in response to PDGF stimulation, we reconstituted PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 null cells with wild type or Y771F/Y1003F form of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1, where both Tyr are mutated to Phe. Phosphorylation of the immunoprecipitated PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 771/1003F protein was significantly reduced in response to PDGF when compared with wild-type PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 (<a href="#f5">Fig. 5d</a>). These results demonstrate that Tyr 771 and Tyr 1003 are targets of phosphorylation downstream of PDGF stimulation.</span><br xmlns=""><br xmlns=""><a xmlns="" name="Functional consequence of PLC-|[gamma]|1 phosphorylation by c-Abl."></a><span xmlns="" class="articletext"><b>Functional consequence of PLC-<img border=0 src="/__chars/gamma/black/bold/base/glyph.gif" align="middle" alt="bold gamma">1 phosphorylation by c-Abl.</b></span><br xmlns=""><span xmlns="" class="articletext">To determine whether phosphorylation of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 by c-Abl affected activity of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1, we co-expressed c-Abl and PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 in 293T cells and assessed PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 activity by analysis of inositol phosphates using high pressure liquid chromatography (HPLC). Overexpression of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 (but not a lipase-inactive PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 protein) induced a two to threefold increase in activity that was reflected by increased levels of Ins(1,4,5)P<sub>3</sub> (<a href="#f7">Fig. 7a</a>). Overexpression of wild-type or kinase-inactive (KR) c-Abl alone did not change Ins(1,4,5)P<sub>3</sub> levels (<a href="#f7">Fig. 7a</a>). Co-expression of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 with wild-type c-Abl resulted in decreased PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 activity, as measured by a consistent decrease in Ins(1,4,5)P<sub>3</sub> (<a href="#f7">Fig. 7a</a>). This effect was not observed when a kinase-inactive form of c-Abl was co-expressed with PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1. Therefore, phosphorylation of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 by c-Abl may serve as a feedback mechanism to turn off PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 activity.</span><br xmlns=""><br xmlns=""><a xmlns="" name="f7"></a><table xmlns="" cellpadding="10" cellspacing="0" border="0" width="470"><tr><td><img alt="" height="2" width="1" src="/images/spacer.gif"></td></tr><tr><td bgcolor="#DFE9FD"><table cellpadding="0" cellspacing="0" border="0" width="430"><tr><td class="articletext" colspan="2"><b><a onclick="window.open('/ncb/journal/v5/n4/fig_tab/ncb949_F7.html','Figure_window','toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=yes,copyhistory=yes,width=617,top=20,left=20');return false;" href="/ncb/journal/v5/n4/fig_tab/ncb949_F7.html">Figure&nbsp;7.</a>&nbsp;c-Abl phosphorylation of PLC-<img border=0 src="/__chars/gamma/black/bold/base/glyph.gif" align="middle" alt="bold gamma">1 causes downregulation of PLC activity.</b></td></tr><tr><td height="15"><img alt="" height="1" width="160" src="/images/spacer.gif"></td><td height="15"><img alt="" height="1" width="270" src="/images/spacer.gif"></td></tr><tr><td width="160" valign="top"><a onclick="window.open('/ncb/journal/v5/n4/fig_tab/ncb949_F7.html','Figure_window','toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=yes,copyhistory=yes,width=617,top=20,left=20');return false;" href="/ncb/journal/v5/n4/fig_tab/ncb949_F7.html"><img border="0" alt="Figure&nbsp;7 thumbnail" src="/ncb/journal/v5/n4/thumbs/ncb949-f7.jpg"></a></td><td class="blacksml" width="270" valign="top"><p class="blacksml"><b>a</b>, 293T cells were cotransfected with PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 and c-Abl constructs, and labeled with <sup>3</sup>H-myoinositol. Labeled inositol phosphates were analysed by HPLC. To correct for differences in cell number, the amount of Ins(1,4,5)P<sub>3</sub> was normalized to InsP<sub>6</sub>, which does not change after PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 expression. The graph is representative of three independent experiments, each performed either in triplicate (above) or duplicate. A separate set of cells was transfected and probed for PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 or c-Abl expression (right). c-Abl-WT and c-Abl-KR were cloned into different vectors, pcDNA3 (WT) and pSR<img border=0 src="/__chars/alpha/black/med/base/glyph.gif" align="bottom" alt="alpha"> (KR), respectively, so that the expression of c-Abl-KR was equal to that of c-Abl&#150;WT. The two different empty vectors were transfected with PLC as controls. WT = wild-type, LI = lipase-inactive, KR = kinase-inactive. <b>b</b>, Arg/Abl double null MEFs (solid bars) or the same MEFs reconstituted with c-Abl and Arg (Arg+/Abl+) by retroviral infection (open bars) were stimulated with PDGF-BB for the indicated times or left unstimulated, followed by treatment of all plates with lithium chloride (10 min). Labeled inositol phosphates were analysed as above, and Ins(1,3,4)P<sub>3</sub> levels were normalized to InsP<sub>6</sub>.</p><br><br><a onclick="window.open('/ncb/journal/v5/n4/fig_tab/ncb949_F7.html','Figure_window','toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=yes,copyhistory=yes,width=617,top=20,left=20');return false;" href="/ncb/journal/v5/n4/fig_tab/ncb949_F7.html"><img border="0" align="bottom" alt="Full Figure" height="11" width="17" src="/ncb/images/fullsize_icon.gif"></a><a class="sml" onclick="window.open('/ncb/journal/v5/n4/fig_tab/ncb949_F7.html','Figure_window','toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=yes,copyhistory=yes,width=617,top=20,left=20');return false;" href="/ncb/journal/v5/n4/fig_tab/ncb949_F7.html">Full Figure and legend (42K)</a></td></tr></table></td></tr><tr><td><img alt="" height="2" width="1" src="/images/spacer.gif"></td></tr></table><span xmlns="" class="articletext">To determine whether c-Abl downregulates PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 in response to PDGF, we compared InsP<sub>3</sub> production after PDGF stimulation of quiescent mouse embryonic fibroblasts (MEFs) lacking Arg and c-Abl with that observed in the null MEFs reconstituted with c-Abl and Arg. Lithium chloride is used to trap downstream metabolites of Ins(1,4,5)P<sub>3</sub>, which is short-lived after PDGF stimulation. In response to PDGF stimulation, Ins(1,4,5)P<sub>3</sub> is rapidly converted to Ins(1,3,4,5)P<sub>4</sub> by phosphorylation and this product in turn is converted to Ins(1,3,4)P<sub>3</sub>. Lithium chloride treatment inhibits the 1-phosphatase that dephosphorylates Ins(1,3,4)P<sub>3</sub>, producing a large accumulation of Ins(1,3,4)P<sub>3</sub> and thereby allowing indirect measurement of Ins(1,4,5)P<sub>3</sub> production by measuring Ins(1,3,4)P<sub>3</sub>. To examine the downregulation of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 after PDGF stimulation, lithium chloride was added at various times after PDGF stimulation. Arg/Abl null MEFs exhibited significantly greater levels of Ins(1,3,4)P<sub>3</sub> produced 5 and 10 min after PDGF stimulation, compared with the same MEFs reconstituted with normal cellular levels of c-Abl and Arg (<a href="#f7">Fig. 7b</a>). Thus, loss of the c-Abl and Arg tyrosine kinases impairs the normal downregulation of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 observed in PDGF-stimulated cells. These data reveal that the Abl family kinases, in addition to functioning downstream of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1, are also important in downregulation of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 activity <i>in vivo</i> in response to growth factor stimulation.</span><br xmlns=""><br xmlns=""><table xmlns="" cellpadding="0" cellspacing="0" border="0" width="470"><tr><td rowspan="2" height="20"><img alt="" height="20" width="1" src="/images/spacer.gif"></td><td align="right"><img alt="" height="3" width="5" src="/ncb/images/arrow_black_up.gif">&nbsp;<a class="top" href="#top">Top</a></td></tr><tr><td height="7" align="right"><img alt="" height="7" width="1" src="/images/spacer.gif"></td></tr><tr><td colspan="2" height="1"><img alt="" height="1" width="470" src="/ncb/images/spacer_grey.gif"></td></tr><tr><td colspan="2" height="20"><img alt="" height="20" width="1" src="/images/spacer.gif"></td></tr></table><a xmlns="" name="Discussion"></a><span xmlns="" class="heading3">Discussion</span><br xmlns=""><span xmlns="" class="articletext">c-Abl is activated by a variety of stimuli. However, little is known regarding the mechanisms of c-Abl activation by these various upstream signals. Here we demostrate that activation of c-Abl by PDGF stimulation is dependent on the earlier activation of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1, thus uncovering a novel link between the c-Abl non-receptor Tyr kinase and phosphoinositide turnover catalysed by PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1. The mechanism of c-Abl activation downstream of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 involves the release of PtdIns(4,5)P<sub>2</sub>-mediated inhibition of the c-Abl kinase activity (<a href="#f8">Fig. 8</a>). Activation of the c-Abl kinase by PDGF is potentiated by phosphorylation by the Src family kinases<sup><a href="#B4">4, 
</a></sup><sup><a href="#B33">33</a></sup> (<a href="#f8">Fig. 8</a>).</span><br xmlns=""><br xmlns=""><a xmlns="" name="f8"></a><table xmlns="" cellpadding="10" cellspacing="0" border="0" width="470"><tr><td><img alt="" height="2" width="1" src="/images/spacer.gif"></td></tr><tr><td bgcolor="#DFE9FD"><table cellpadding="0" cellspacing="0" border="0" width="430"><tr><td class="articletext" colspan="2"><b><a onclick="window.open('/ncb/journal/v5/n4/fig_tab/ncb949_F8.html','Figure_window','toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=yes,copyhistory=yes,width=617,top=20,left=20');return false;" href="/ncb/journal/v5/n4/fig_tab/ncb949_F8.html">Figure&nbsp;8.</a>&nbsp;Model of the interaction between c-Abl and PLC-<img border=0 src="/__chars/gamma/black/bold/base/glyph.gif" align="middle" alt="bold gamma">1 signalling pathways.</b></td></tr><tr><td height="15"><img alt="" height="1" width="160" src="/images/spacer.gif"></td><td height="15"><img alt="" height="1" width="270" src="/images/spacer.gif"></td></tr><tr><td width="160" valign="top"><a onclick="window.open('/ncb/journal/v5/n4/fig_tab/ncb949_F8.html','Figure_window','toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=yes,copyhistory=yes,width=617,top=20,left=20');return false;" href="/ncb/journal/v5/n4/fig_tab/ncb949_F8.html"><img border="0" alt="Figure&nbsp;8 thumbnail" src="/ncb/journal/v5/n4/thumbs/ncb949-f8.jpg"></a></td><td class="blacksml" width="270" valign="top"><p class="blacksml"><b>a</b>, Before PDGF stimulation, c-Abl activity is partly suppressed through a mechanism involving PtdIns(4,5)P<sub>2</sub>. This model is also consistent with the existence of c-Abl inhibitory intramolecular interactions that may be stabilized by the binding of PtdIns(4,5)P<sub>2</sub>-binding proteins (X) to c-Abl. Before PDGF stimulation, a c-Abl&#150;PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 complex is detected that may be dependent on direct or indirect (Y) binding between the two proteins. <b>b</b>, PDGF stimulation enhances the interaction between c-Abl and PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1, which is mediated by SH2-phosphotyrosine binding, and may be strengthened by SH3&#150;proline sequence interactions between the two proteins. Activated PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 hydrolyses PtdIns(4,5)P<sub>2</sub>, releasing c-Abl kinase inhibition. Full activation of c-Abl by PDGF also requires phosphorylation of c-Abl by Src family kinases. <b>c</b>, The activated c-Abl in turn phosphorylates and downregulates PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1. After c-Abl-induced PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 downregulation, PtdIns(4,5)P<sub>2</sub> levels increase, thereby inhibiting the c-Abl kinase and returning its activity to basal levels. Black arrows denote protein&#150;protein interactions and dotted black arrows represent possible interactions. Red arrows correspond to positive regulatory phosphorylation events, whereas yellow arrows are negative regulatory phosphorylation events.</p><br><br><a onclick="window.open('/ncb/journal/v5/n4/fig_tab/ncb949_F8.html','Figure_window','toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=yes,copyhistory=yes,width=617,top=20,left=20');return false;" href="/ncb/journal/v5/n4/fig_tab/ncb949_F8.html"><img border="0" align="bottom" alt="Full Figure" height="11" width="17" src="/ncb/images/fullsize_icon.gif"></a><a class="sml" onclick="window.open('/ncb/journal/v5/n4/fig_tab/ncb949_F8.html','Figure_window','toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=yes,copyhistory=yes,width=617,top=20,left=20');return false;" href="/ncb/journal/v5/n4/fig_tab/ncb949_F8.html">Full Figure and legend (85K)</a></td></tr></table></td></tr><tr><td><img alt="" height="2" width="1" src="/images/spacer.gif"></td></tr></table><span xmlns="" class="articletext">Inhibition of c-Abl kinase activity by PtdIns(4,5)P<sub>2</sub> provides a unique mechanism of c-Abl regulation. The kinase activity of c-Abl is tightly regulated in the cell by intra- and inter-molecular interactions. Purification of c-Abl increases its kinase activity, as does overexpression (20&#150;50 fold)<sup><a href="#B30">30, 
</a></sup><sup><a href="#B34">34, 
</a></sup><sup><a href="#B35">35</a></sup>. These findings suggest the presence of a soluble inhibitor that may be titrated out by overexpression or removed by purification<sup><a href="#B30">30, 
</a></sup><sup><a href="#B34">34, 
</a></sup><sup><a href="#B35">35</a></sup>. Several potential direct inhibitors of c-Abl have been described, including PAG, RB and AAP-1 (refs <a href="#B1">1</a>, <a href="#B36">36</a>) and more recently, F-actin<sup><a href="#B21">21</a></sup>. However, the importance of these proteins in regulating c-Abl in physiologically relevant processes remain unclear. Intramolecular interactions may also contribute to the negative regulation of c-Abl. Constitutive activation of the c-Abl kinase may result through disruption of intramolecular SH3-proline sequence interactions, by deletion or point mutation of the c-Abl SH3 domain, or mutation of proline residues in the linker region between the SH2 and catalytic domains<sup><a href="#B37">37, 
</a></sup><sup><a href="#B38">38</a></sup>. It has also been proposed that c-Abl is auto-inhibited by its first 81 amino acids<sup><a href="#B39">39</a></sup>. After activation by PDGF, c-Abl is downregulated by dephosphorylation through the action of the PEST-type protein tyrosine phosphatases<sup><a href="#B40">40</a></sup>. Activated c-Abl is also downregulated by ubiquitin-dependent degradation<sup><a href="#B41">41</a></sup>.</span><br xmlns=""><br xmlns=""><span xmlns="" class="articletext">A model for c-Abl activation has been proposed, on the basis of enzymatic analysis of c-Abl<sup><a href="#B35">35</a></sup>. In this model, c-Abl exists in an unphosphorylated inhibited conformation and purification of c-Abl or a signalling event that results in removal of inhibitory interactions causes c-Abl activation. Activation can also be induced by phosphorylation of Tyr 412 in the SH1 domain and Tyr 245 in the linker region, which disrupts the SH3&#150;linker interaction, and results in the full activation of c-Abl<sup><a href="#B35">35</a></sup>. Our results are in agreement with this model. We suggest that PtdIns(4,5)P<sub>2</sub> (and possibly other molecules bound to PtdIns(4,5)P<sub>2</sub>) are involved in maintaining c-Abl in an inactive or low activity state before PDGF stimulation and that activation of c-Abl by PDGF occurs only after PtdIns(4,5)P<sub>2</sub> is destroyed either by hydrolysis (PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1-mediated) or dephosphorylation (inositol polyphosphate 5-phoshatase-dependent; <a href="#f8">Fig. 8</a>). c-Abl is further activated through phosphorylation by the Src family kinases on Tyr 412 and a second site, Tyr 245<sup><a href="#B4">4, 
</a></sup><sup><a href="#B33">33</a></sup>. These events may occur concurrently in PDGF-stimulated cells.</span><br xmlns=""><br xmlns=""><span xmlns="" class="articletext">PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 and c-Abl form a complex <i>in vivo</i> and after kinase activation, c-Abl phosphorylates PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1, causing inhibition of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 activity (<a href="#f8">Fig. 8</a>). Unlike the PDGFR, c-Abl does not phosphorylate positive regulatory residues on PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 <i>in vivo</i>. Downregulation of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 by c-Abl <i>in vivo</i> may involve phosphorylation of Tyr 771, which negatively regulates PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 <i>in vitro</i><sup><a href="#B6">6</a></sup>, as c-Abl phosphorylates Tyr 771 both <i>in vitro</i> and <i>in vivo</i>. Additionally, c-Abl expression elicits phosphorylation of Tyr 1003 in the PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 Y-catalytic domain. Tyr 1003 has not previously been identified as a target of other Tyr kinases and therefore Tyr 1003 represents a novel phosphorylation site that may contribute to downregulation of PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 by c-Abl.</span><br xmlns=""><br xmlns=""><span xmlns="" class="articletext">PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 has been implicated in the control of cell migration, axon guidance and neurite outgrowth<sup><a href="#B8">8, 
</a></sup><sup><a href="#B9">9, 
</a></sup><sup><a href="#B10">10</a></sup>. The Abl kinases are important in the positive regulation of axon guidance and neurite outgrowth<sup><a href="#B20">20, 
</a></sup><sup><a href="#B42">42</a></sup>, and in negative regulation of migration of fibroblast and epithelial cells (R.P. and A.M.P., unpublished results)<sup><a href="#B18">18, 
</a></sup><sup><a href="#B19">19</a></sup>. These findings may be explained by the potential dual roles of c-Abl in modulating actin polymerization at the leading edge, while also signalling at focal adhesions<sup><a href="#B2">2, 
</a></sup><sup><a href="#B19">19</a></sup>. Here, we show that both c-Abl and PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 positively regulate chemotaxis toward PDGF-BB in PAE cells expressing a PDGFR-<img border=0 src="/__chars/beta/black/med/base/glyph.gif" align="middle" alt="beta">. Therefore, the PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1-dependent activation of c-Abl is physiologically relevant, as PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 requires c-Abl kinase activity to enhance chemotaxis towards PDGF.</span><br xmlns=""><br xmlns=""><span xmlns="" class="articletext">Our findings suggest that Abl family kinases may be important in signalling downstream of PtdIns(4,5)P<sub>2</sub> in multiple signalling pathways. PtdIns(4,5)P<sub>2</sub> has been implicated in the regulation of a variety of cellular processes, in addition to modulating cytoskeletal dynamics. Among these processes are endocytosis, exocytosis, vesicle targeting and synaptic plasticity<sup><a href="#B43">43</a></sup>. Additionally, c-Abl regulates PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 and thereby affects the turnover of phospholipids. Together, these findings reveal the existence of bidirectional regulation of Abl Tyr kinases and lipid signalling pathways.</span><br xmlns=""><br xmlns=""><table xmlns="" cellpadding="0" cellspacing="0" border="0" width="470"><tr><td rowspan="2" height="20"><img alt="" height="20" width="1" src="/images/spacer.gif"></td><td align="right"><img alt="" height="3" width="5" src="/ncb/images/arrow_black_up.gif">&nbsp;<a class="top" href="#top">Top</a></td></tr><tr><td height="7" align="right"><img alt="" height="7" width="1" src="/images/spacer.gif"></td></tr><tr><td colspan="2" height="1"><img alt="" height="1" width="470" src="/ncb/images/spacer_grey.gif"></td></tr><tr><td colspan="2" height="20"><img alt="" height="20" width="1" src="/images/spacer.gif"></td></tr></table><a xmlns="" name="Methods"></a><span xmlns="" class="heading3">Methods</span><br xmlns=""><a xmlns="" name="Materials"></a><span xmlns="" class="articletext"><b>Materials</b></span><br xmlns=""><span xmlns="" class="articletext">U73122 and its inactive analogue U-73343 were purchased from BioMol Research Labs (Plymouth Meeting, PA). Antibodies directed against c-Abl (K12, Santa Cruz Biotechnologies, Santa Cruz, CA; AB-3, Oncogene, San Diego, CA; 8E9, Pharmingen, San Diego, CA), the AU1 tag (Covance/Babco, Richmond, CA), antiphosphotyrosine (4G10, UBI; PY99, Santa Cruz) and GST (Santa Cruz,) were purchased commercially. Antibodies directed against the extracellular domain of PDGFR-<img border=0 src="/__chars/alpha/black/med/base/glyph.gif" align="bottom" alt="alpha"> (80.8), the intracellular domain of PDGFR-<img border=0 src="/__chars/beta/black/med/base/glyph.gif" align="middle" alt="beta"> (30A; ref. <a href="#B23">23</a>), PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 (ref. <a href="#B44">44</a>) and c-Abl (Pex4; ref. <a href="#B4">4</a>) were previously described. Phospholipids were purchased from Avanti Polar Lipids (Alabaster, AL) and <sup>3</sup>H-myoinositol was purchased from American Radiolabeled Chemicals Inc (St Louis, MO). PDGF-AA and PDGF-BB were obtained from Upstate Biotechnologies (Lake Placid, NY).</span><br xmlns=""><br xmlns=""><a xmlns="" name="DNA constructs"></a><span xmlns="" class="articletext"><b>DNA constructs</b></span><br xmlns=""><span xmlns="" class="articletext">Chimeric PDGF <img border=0 src="/__chars/alpha/black/med/base/glyph.gif" align="bottom" alt="alpha">/<img border=0 src="/__chars/beta/black/med/base/glyph.gif" align="middle" alt="beta"> receptors containing F1021 and F72/74/1021 mutations were created by swapping a fragment containing F1021 from a PDGFR-<img border=0 src="/__chars/beta/black/med/base/glyph.gif" align="middle" alt="beta"> mutant<sup><a href="#B45">45</a></sup> into wild-type chimeric receptors<sup><a href="#B23">23</a></sup>. pcDNA3-c-Abl (murine) was obtained from R. V. Etten. Migr1&#150;c-Abl, pSR<img border=0 src="/__chars/alpha/black/med/base/glyph.gif" align="bottom" alt="alpha">&#150;c-Abl&#150;KR and PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 mutants (Y783F, LI (H335F), N<sup>*</sup>-SH2(R586K),C<sup>*</sup>-SH2 (R694K), N<sup>*</sup>C<sup>*</sup>-SH2 (R586/694K)) were described previously<sup><a href="#B4">4, 
</a></sup><sup><a href="#B44">44</a></sup>. Constructs of c-Abl and v-Abl were cloned into the bicistronic vector Mig-CD4 (obtained from W. Pear). Migr1&#150;PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 was created by blunting the PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 <i>Xba</i>I fragment and cloning into the blunted EcoR1 site of Migr1. PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 mutants were created using Quikchange mutagenesis (Stratagene, Cedar Creek, TX). pBabe-puro Inp54 (ref. <a href="#B26">26</a>) was created by removing the phosphatase from a green fluorescent protein (GFP)&#150;myristoylated version<sup><a href="#B27">27</a></sup>, without the GFP tag or Lyn myristoylation sequence. A phosphatase-dead 5-ptase construct was created by mutating pBabepuro-Inp54 D280 to Ala by mutagenesis (QuikChange, Stratagene, Cedar Creek, TX). All PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 and Inp54 mutants were sequenced.</span><br xmlns=""><br xmlns=""><a xmlns="" name="Cell lines"></a><span xmlns="" class="articletext"><b>Cell lines</b></span><br xmlns=""><span xmlns="" class="articletext">Ph cells, which lack endogenous PDGFR-<img border=0 src="/__chars/alpha/black/med/base/glyph.gif" align="bottom" alt="alpha">, and Ph cells expressing wild-type and mutant chimeric PDGFRs were previously described<sup><a href="#B23">23</a></sup>. <i>PLC-<img border=0 src="/__chars/gamma/black/ital/base/glyph.gif" align="middle" alt="italic gamma">1</i>-null fibroblasts were a kind gift of G. Carpenter and were maintained as described<sup><a href="#B24">24</a></sup>. <i>PLC-<img border=0 src="/__chars/gamma/black/ital/base/glyph.gif" align="middle" alt="italic gamma">1</i>-null fibroblasts were reconstituted with PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 by retroviral infection with Migr1&#150;PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1, followed by FACS to sort for GFP-positive cells. <i>Arg</i>/<i>Abl</i> double null MEFs (a kind gift of A. Koleske, Yale University, New Haven, CT) were reconstituted with vector (Migr1) or c-Abl as previously described<sup><a href="#B4">4</a></sup>. The bicistronic PK1&#150;Arg construct was introduced into MEFs by liposome-mediated transfection followed by puromycin selection. PAE cells were infected with the PDGFR-<img border=0 src="/__chars/beta/black/med/base/glyph.gif" align="middle" alt="beta"> in a LXSH retroviral vector, followed by hygromycin selection to produce a stable cell line.</span><br xmlns=""><br xmlns=""><a xmlns="" name="GST fusion proteins"></a><span xmlns="" class="articletext"><b>GST fusion proteins</b></span><br xmlns=""><span xmlns="" class="articletext">GST&#150;PLC<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">-N-SH2 and GST&#150;PLC<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">&#150;N+C-SH2 were obtained from T. Pawson. GST&#150;PLC<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">&#150;C&#150;SH2 and GST&#150;PLC<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">&#150;N+C&#150;SH2&#150;SH3 were previously described<sup><a href="#B23">23, 
</a></sup><sup><a href="#B46">46</a></sup>. GST&#150;PLC<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">-SH3 was constructed by PCR amplification and cloning into pGEX&#150;KG. GST&#150;PLC<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">&#150;C&#150;SH2 (R694) was obtained by mutating the GST&#150;PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">&#150;C-SH2 construct<sup><a href="#B46">46</a></sup> using transformer mutagenesis (Clonetech,Palo Alto, CA). GST&#150;Crk and GST fusion proteins containing fragments of c-Abl were previously described<sup><a href="#B4">4</a></sup>.</span><br xmlns=""><br xmlns=""><a xmlns="" name="Immunoprecipitation, western blotting, GST pulldown and kinase assays"></a><span xmlns="" class="articletext"><b>Immunoprecipitation, western blotting, GST pulldown and kinase assays</b></span><br xmlns=""><span xmlns="" class="articletext">Cells were lysed in a Triton lysis buffer (used for kinase assays, GST pulldowns, co-immunoprecipitations) or RIPA buffer (used for immunoprecipitation-phosphotyrosine assays). Kinase assays were performed as previously described<sup><a href="#B4">4</a></sup>. PIPs in chloroform:methanol were dried down, resuspended in 10 mM Tris at pH 7.5 and sonicated to create liposomes. Liposomes were added directly to the kinase assay, in the absence or presence of calcuim chloride. Significant inhibition of c-Abl kinase activity by PtdIns(4,5)P<sub>2</sub> (6&#150;15-fold) with no effect of PtdIns(4)P was observed for all batches of lipids at concentrations of 40&#150;60 <img border=0 src="/__chars/mu/black/med/base/glyph.gif" align="middle" alt="mu">M lipid and 400&#150;800 <img border=0 src="/__chars/mu/black/med/base/glyph.gif" align="middle" alt="mu">M calcuim chloride.</span><br xmlns=""><br xmlns=""><a xmlns="" name="Identification of phosphorylation sites by mass spectrometry"></a><span xmlns="" class="articletext"><b>Identification of phosphorylation sites by mass spectrometry</b></span><br xmlns=""><span xmlns="" class="articletext">GST&#150;PLC<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">&#150;C-SH2 and GST&#150;PLC<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">&#150;N+C-SH2&#150;SH3 were phosphorylated in a cold kinase reaction utilizing immunoprecipitated c-Abl from 293T cells transfected with murine c-Abl. The extent of phosphorylation was determined by direct analysis of the kinase reaction by liquid chromatography/mass spectrometry (LC/MS) using an HP1090 liquid chromatography system and a Sciex (Toronto, Ontario, Canada) API-III mass spectrometer. Protein mass spectra were deconvoluted from mass/charge to molecular weight using the BioSpec Reconstruct (Sciex, Toronto, Ontario, Canada) routine within the BioMultiview (Sciex, Toronto, Ontario, Canada) data processing software for the API-III. Specific sites of phosphorylation were identified by liquid chromatography/tandem mass spectrometric analysis (LC/MS/MS) of proteolytic digests of the kinase reaction mixtures. To determine site-specific phosphorylation stoichiometry, reconstructed ion chromatograms were plotted from LC/MS analyses of proteolytic digests of the kinase reaction mixtures for both phosphorylated and nonphosphorylated forms of each phosphopeptide. Peaks corresponding to phosphorylated and nonphosphorylated forms of each peptide were integrated and the percentage of phosphorylation for each site was calculated on the basis of peak areas.</span><br xmlns=""><br xmlns=""><span xmlns="" class="articletext">Identification of <i>in vivo</i> phosphorylation sites on PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 was performed by co-expressing c-Abl and PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 in 293T cells and immunoprecipitating PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1. Phosphorylation sites on PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 were identified by the Harvard Microchemistry Facility (Cambridge, MA) using microcapillary reverse-phase HPLC nano-electrospray tandem mass spectrometry on a Finnigan (San Jose, CA) LCQ DECA quadrupole ion trap mass spectrometer. TIMM was conducted on the peptide containing Tyr 783 as previously described<sup><a href="#B31">31</a></sup>.</span><br xmlns=""><br xmlns=""><a xmlns="" name="Analysis of inositol phosphates by HPLC"></a><span xmlns="" class="articletext"><b>Analysis of inositol phosphates by HPLC</b></span><br xmlns=""><span xmlns="" class="articletext">After transfection of 293T cells, the media was replaced with inositol-free DMEM containing 10% dialysed foetal bovine serum (FBS) (Gibco-BRL, Invitrogen Life Technologies, Carlsbad, CA) and <sup>3</sup>H-myoinositol (10 <img border=0 src="/__chars/mu/black/med/base/glyph.gif" align="middle" alt="mu">Ci ml<sup>-1</sup>). After 60&#150;70 h, cells were lysed in 1M hydrochloric acid and the soluble supernatant was loaded onto the HPLC. Arg/Abl double-null MEFs and double-null MEFs reconstituted with Arg and c-Abl were labelled with <sup>3</sup>H-myoinositol for 48 h in 15% serum. These cells were serum-starved for 48 h in medium containing label and 0.2% serum and then stimulated with PDGF-BB or left unstimulated. Lithium chloride (10 mM) was added at the indicated times for 10 min before cell lysis and lipid analysis.</span><br xmlns=""><br xmlns=""><a xmlns="" name="Transwell migration assays"></a><span xmlns="" class="articletext"><b>Transwell migration assays</b></span><br xmlns=""><span xmlns="" class="articletext">PAE cells expressing a PDGFR-<img border=0 src="/__chars/beta/black/med/base/glyph.gif" align="middle" alt="beta"> were transfected with the indicated DNAs using Fugene (Roche, Indianapolis, IN). Two days later, cells were serum starved overnight in DMEM alone. Transwell chemotaxis assays were performed by coating the bottom surface of the transwell membrane (Costar, Corning, NY) with collagen (Collaborative Research; BDBiosciences, Bedford, MA) (100 <img border=0 src="/__chars/mu/black/med/base/glyph.gif" align="middle" alt="mu">g ml<sup>-1</sup>) for 2 h at 37 &#176;C. Cells were trypsinized, washed in migration media (DMEM/1% BSA), resuspended to 1 <img border=0 src="/__chars/math/special/times/black/med/base/glyph.gif" align="bottom" alt="times"> 10<sup>6</sup> cells per ml and filtered through a 70-<img border=0 src="/__chars/mu/black/med/base/glyph.gif" align="middle" alt="mu">m nylon strainer to remove clumped cells. Transwells were washed with DMEM and migration media was placed in the bottom well with or without PDGF. 200 <img border=0 src="/__chars/mu/black/med/base/glyph.gif" align="middle" alt="mu">l of cell suspension in migration media was placed in the upper wells and cells were allowed to migrate for 4 h. After migration, cells on the upper surface were removed and cells on the bottom surface were fixed in 4% paraformaldehyde for 10 min and stained with DAPI (0.0002%) for 5 s. Cells were mounted in antifade solution and transfected cells (GFP-positive) were counted (8&#150;20<img border=0 src="/__chars/math/special/times/black/med/base/glyph.gif" align="bottom" alt="times"> fields each).</span><br xmlns=""><br xmlns=""><table xmlns="" cellpadding="0" cellspacing="0" border="0" width="470"><tr><td rowspan="2" height="20"><img alt="" height="20" width="1" src="/images/spacer.gif"></td><td align="right"><img alt="" height="3" width="5" src="/ncb/images/arrow_black_up.gif">&nbsp;<a class="top" href="#top">Top</a></td></tr><tr><td height="7" align="right"><img alt="" height="7" width="1" src="/images/spacer.gif"></td></tr><tr><td colspan="2" height="1"><img alt="" height="1" width="470" src="/ncb/images/spacer_grey.gif"></td></tr><tr><td colspan="2" height="20"><img alt="" height="20" width="1" src="/images/spacer.gif"></td></tr></table><span xmlns="" class="articletext">Received 15 May 2002; </span><span xmlns="" class="articletext">Accepted 24 January 2003; </span><span xmlns="" class="articletext">Published online 24 March 2003.</span><br xmlns=""><br xmlns=""><a xmlns="" name="References"></a><span xmlns="" class="heading3">REFERENCES </span><ol xmlns="" class="articletext"><li><A name="B1"></a>
Pendergast, A.M. The Abl family Kinases: mechanisms of regulation and signaling. <i>Adv. Cancer Res.</i> <b>85</b>, 51&#150;100 (2002).&nbsp;|&nbsp;<a 
href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=npg&cmd=Retrieve&db=PubMed&list_uids=12374288&dopt=Abstract" target="external"><span 
class="intlink">PubMed</span></a> &nbsp;|&nbsp;<a href="http://links.isiglobalnet2.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=Nature&SrcApp=Nature&DestLinkType=FullRecord&KeyUT=000178758300003&DestApp=WOS_CPL" target="external">ISI</a>&nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DC%2BD38XpsVyisrc%3D&pissn=1465-7392&pyear=2003&md5=18376bfe940ddb66eeb00792748da979" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B2"></a>
Lewis, J.M., Baskaran, R., Taagepera, S., Schwartz, M.A. &amp; Wang, J.Y.J. Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport. <i>Proc. Natl Acad. Sci. USA</i> <b>93</b>, 15174&#150;15179 (1996).&nbsp;|&nbsp;<a href="http://dx.doi.org/10.1073%2Fpnas.93.26.15174" target="external">Article</a>&nbsp;|&nbsp;<a 
href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=npg&cmd=Retrieve&db=PubMed&list_uids=8986783&dopt=Abstract" target="external"><span 
class="intlink">PubMed</span></a> &nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DyaK2sXntVCq&pissn=1465-7392&pyear=2003&md5=5c5e19deb2cd65129f7ab99e9ae7e818" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B3"></a>
Zipfel, P.A. <i>et al</i>. The c-Abl tyrosine kinase is regulated downstream of the B cell antigen receptor and interacts with CD19. <i>J. Immunol.</i> <b>165</b>, 6872&#150;6879 (2000).&nbsp;|&nbsp;<a 
href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=npg&cmd=Retrieve&db=PubMed&list_uids=11120811&dopt=Abstract" target="external"><span 
class="intlink">PubMed</span></a> &nbsp;|&nbsp;<a href="http://links.isiglobalnet2.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=Nature&SrcApp=Nature&DestLinkType=FullRecord&KeyUT=000165790500029&DestApp=WOS_CPL" target="external">ISI</a>&nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DC%2BD3cXovFyhurk%3D&pissn=1465-7392&pyear=2003&md5=b754aa56fadadbe9d838529d0962eb71" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B4"></a>
Plattner, R., Kadlec, L., DeMali, K.A., Kazlauskas, A. &amp; Pendergast, A.M. c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. <i>Genes Dev.</i> <b>13</b>, 2400&#150;2411 (1999).&nbsp;|&nbsp;<a href="http://dx.doi.org/10.1101%2Fgad.13.18.2400" target="external">Article</a>&nbsp;|&nbsp;<a 
href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=npg&cmd=Retrieve&db=PubMed&list_uids=10500097&dopt=Abstract" target="external"><span 
class="intlink">PubMed</span></a> &nbsp;|&nbsp;<a href="http://links.isiglobalnet2.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=Nature&SrcApp=Nature&DestLinkType=FullRecord&KeyUT=000082810600007&DestApp=WOS_CPL" target="external">ISI</a>&nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DyaK1MXmsVCgsbc%3D&pissn=1465-7392&pyear=2003&md5=3b789ed7ed9b630000c24ca262546e72" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B5"></a>
Rebecchi, M.J. &amp; Pentyala, S.N. Structure, function and control of phosphoinositide-specific phospholipase C. <i>Physiol. Rev.</i> <b>80</b>, 1291&#150;1335 (2000).&nbsp;|&nbsp;<a 
href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=npg&cmd=Retrieve&db=PubMed&list_uids=11015615&dopt=Abstract" target="external"><span 
class="intlink">PubMed</span></a> &nbsp;|&nbsp;<a href="http://links.isiglobalnet2.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=Nature&SrcApp=Nature&DestLinkType=FullRecord&KeyUT=000089628600002&DestApp=WOS_CPL" target="external">ISI</a>&nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DC%2BD3cXnsVKisL0%3D&pissn=1465-7392&pyear=2003&md5=ab05d8d8042b8e5e47d3e747ebd5ff90" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B6"></a>
Kim, H.K. <i>et al</i>. PDGF stimulation of inositol phospholipid hydrolysis requires PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 phosphorylation on tyrosine residues 783 and 1254. <i>Cell</i> <b>65</b>, 435&#150;441 (1991).&nbsp;|&nbsp;<a 
href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=npg&cmd=Retrieve&db=PubMed&list_uids=1708307&dopt=Abstract" target="external"><span 
class="intlink">PubMed</span></a> &nbsp;|&nbsp;<a href="http://links.isiglobalnet2.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=Nature&SrcApp=Nature&DestLinkType=FullRecord&KeyUT=A1991FK18200010&DestApp=WOS_CPL" target="external">ISI</a>&nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DyaK3MXisVWgtbw%3D&pissn=1465-7392&pyear=2003&md5=8354ecf38cf2b48acf4f5152f9f0d921" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B7"></a>
Park, D., Min, H.K. &amp; Rhee, S.G. Inhibition of CD3-linked phospholipase C-gamma 1 by phorbol ester and by cAMP is associated wih decreased phosphotyrosine and increased phosphoserine contents of PLC-gamma 1. <i>J. Biol. Chem.</i> <b>267</b>, 1496&#150;1501 (1992).&nbsp;|&nbsp;<a 
href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=npg&cmd=Retrieve&db=PubMed&list_uids=1370476&dopt=Abstract" target="external"><span 
class="intlink">PubMed</span></a> &nbsp;|&nbsp;<a href="http://links.isiglobalnet2.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=Nature&SrcApp=Nature&DestLinkType=FullRecord&KeyUT=A1992HA48500019&DestApp=WOS_CPL" target="external">ISI</a>&nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DyaK38Xot1ShtQ%3D%3D&pissn=1465-7392&pyear=2003&md5=d6cbbad5ae44ae8dda3d143b533e76b1" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B8"></a>
Kundra, V. <i>et al</i>. Regulation of chemotaxis by the platelet-derived growth factor receptor-<img border=0 src="/__chars/beta/black/med/base/glyph.gif" align="middle" alt="beta">. <i>Nature</i> <b>367</b>, 474&#150;476 (1994).&nbsp;|&nbsp;<a href="/doifinder/10.1038%2F367474a0" target="external">Article</a>&nbsp;|&nbsp;<a 
href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=npg&cmd=Retrieve&db=PubMed&list_uids=8107807&dopt=Abstract" target="external"><span 
class="intlink">PubMed</span></a> &nbsp;|&nbsp;<a href="http://links.isiglobalnet2.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=Nature&SrcApp=Nature&DestLinkType=FullRecord&KeyUT=A1994MU67900058&DestApp=WOS_CPL" target="external">ISI</a>&nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DyaK2cXhsFCgs7w%3D&pissn=1465-7392&pyear=2003&md5=3ae86ce3cfe45c4df7db04171d619c7a" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B9"></a>
Firth, J.D., Putnins, E.E., Larjava, H. &amp; Uitto, V.J. Exogenous phospholipase C stimulates epithelial cell migration and integrin expression in vitro. <i>Wound Repair Regeneration</i> <b>9</b>, 86&#150;94 (2001).&nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:STN:280:DC%2BD3M3lt1yksQ%3D%3D&pissn=1465-7392&pyear=2003&md5=b6474edd1a0c75fce1d765f5e4c1a9c7" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B10"></a>
Song, H. &amp; Poo, M. Signal transduction underlying growth cone guidance by diffusible factors. <i>Curr. Opin Neurobiol.</i> <b>9</b>, 355&#150;363 (1999).&nbsp;|&nbsp;<a href="http://dx.doi.org/10.1016%2FS0959-4388%2899%2980052-X" target="external">Article</a>&nbsp;|&nbsp;<a 
href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=npg&cmd=Retrieve&db=PubMed&list_uids=10395576&dopt=Abstract" target="external"><span 
class="intlink">PubMed</span></a> &nbsp;|&nbsp;<a href="http://links.isiglobalnet2.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=Nature&SrcApp=Nature&DestLinkType=FullRecord&KeyUT=000080942500015&DestApp=WOS_CPL" target="external">ISI</a>&nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DyaK1MXktVyksrg%3D&pissn=1465-7392&pyear=2003&md5=300b22962c71076d01169721bdf8c7ae" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B11"></a>
Yu, H., Fukami, K., Itoh, T. &amp; Takenawa, T. Phosphorylation of phospholipase C<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 on tyrosine residue 783 by platelet-derived growth factor regulates reorganization of the cytoskeleton. <i>Exp. Cell Res.</i> <b>243</b>, 112&#150;122 (1998).&nbsp;|&nbsp;<a href="http://dx.doi.org/10.1006%2Fexcr.1998.4132" target="external">Article</a>&nbsp;|</li>
<li><A name="B12"></a>
Amyere, M. <i>et al</i>. Constitutive macropinocytosis in oncogene-transformed fibroblasts depends on sequential permanent activation of phosphoinositide 3-kinase and phospholipase C. <i>Mol. Biol. Cell</i> <b>11</b>, 3453&#150;3467 (2000).&nbsp;|&nbsp;<a 
href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=npg&cmd=Retrieve&db=PubMed&list_uids=11029048&dopt=Abstract" target="external"><span 
class="intlink">PubMed</span></a> &nbsp;|&nbsp;<a href="http://links.isiglobalnet2.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=Nature&SrcApp=Nature&DestLinkType=FullRecord&KeyUT=000089834800016&DestApp=WOS_CPL" target="external">ISI</a>&nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DC%2BD3cXnslWnt7Y%3D&pissn=1465-7392&pyear=2003&md5=6ca5948af9c5a4a95bf41d9c80d8934a" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B13"></a>
Yamamoto, M. <i>et al</i>. Phosphatidylinositol 4,5-bisphosphate induces actin stress-fiber formation and inhibits membrane ruffling in CV1 cells. <i>J. Cell Biol.</i> <b>152</b>, 867&#150;876 (2001).&nbsp;|&nbsp;<a href="http://dx.doi.org/10.1083%2Fjcb.152.5.867" target="external">Article</a>&nbsp;|&nbsp;<a 
href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=npg&cmd=Retrieve&db=PubMed&list_uids=11238445&dopt=Abstract" target="external"><span 
class="intlink">PubMed</span></a> &nbsp;|&nbsp;<a href="http://links.isiglobalnet2.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=Nature&SrcApp=Nature&DestLinkType=FullRecord&KeyUT=000167408000004&DestApp=WOS_CPL" target="external">ISI</a>&nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DC%2BD3MXhslGmtb0%3D&pissn=1465-7392&pyear=2003&md5=6bc301a3026dc582b82325be5d8f8d52" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B14"></a>
Gilbert, S.H., Perry, K. &amp; Fay, F.S. Mediation of Chemoattractant-induced changes in (Ca<sup>2+</sup>)i and cell shape, polarity, and locomotion by InsP<sub>3</sub>, DAG, and protein kinase C in newt eosinophils. <i>J. Cell Biol.</i> <b>127</b>, 489&#150;503 (1994).&nbsp;|&nbsp;<a 
href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=npg&cmd=Retrieve&db=PubMed&list_uids=7929591&dopt=Abstract" target="external"><span 
class="intlink">PubMed</span></a> &nbsp;|&nbsp;<a href="http://links.isiglobalnet2.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=Nature&SrcApp=Nature&DestLinkType=FullRecord&KeyUT=A1994PM41600017&DestApp=WOS_CPL" target="external">ISI</a>&nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DyaK2cXmt1Kqsrg%3D&pissn=1465-7392&pyear=2003&md5=0e89c56279967f7f95908948333d3c2e" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B15"></a>
Kadlec, L. &amp; Pendergast, A.M. The amphiphysin-like protein 1 (ALP1) interacts functionally with the cABL tyrosine kinase and may play a role in cytoskeletal regulation. <i>Proc. Natl Acad. Sci. USA</i> <b>94</b>, 12390&#150;12395 (1997).&nbsp;|&nbsp;<a href="http://dx.doi.org/10.1073%2Fpnas.94.23.12390" target="external">Article</a>&nbsp;|&nbsp;<a 
href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=npg&cmd=Retrieve&db=PubMed&list_uids=9356459&dopt=Abstract" target="external"><span 
class="intlink">PubMed</span></a> &nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DyaK2sXns1ylsLs%3D&pissn=1465-7392&pyear=2003&md5=0e756397c2b1428d8bab99d217080c3c" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B16"></a>
Koleske, A.J. <i>et al</i>. Essential Roles for the Abl and Arg Tyrosine Kinases in Neurulation. <i>Neuron</i> <b>21</b>, 1259&#150;1272 (1998).&nbsp;|&nbsp;<a 
href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=npg&cmd=Retrieve&db=PubMed&list_uids=9883720&dopt=Abstract" target="external"><span 
class="intlink">PubMed</span></a> &nbsp;|&nbsp;<a href="http://links.isiglobalnet2.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=Nature&SrcApp=Nature&DestLinkType=FullRecord&KeyUT=000077910600009&DestApp=WOS_CPL" target="external">ISI</a>&nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DyaK1MXntVOrtg%3D%3D&pissn=1465-7392&pyear=2003&md5=495db18d8e8826df0b1268c48edec67d" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B17"></a>
Wang, Y., Miller, A.L., Mooseker, M.S. &amp; Koleske, A.J. The Abl-related gene (Arg) non-receptor tyrosine kinase uses two F-actin binding domains to bundle actin. <i>Proc. Natl Acad. Sci. USA</i> <b>98</b>, 14865&#150;70 (2001).&nbsp;|&nbsp;<a href="http://dx.doi.org/10.1073%2Fpnas.251249298" target="external">Article</a>&nbsp;|&nbsp;<a 
href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=npg&cmd=Retrieve&db=PubMed&list_uids=11752434&dopt=Abstract" target="external"><span 
class="intlink">PubMed</span></a> &nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DC%2BD38XptlOj&pissn=1465-7392&pyear=2003&md5=694993892d263c162b0cf4396673eaf7" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B18"></a>
Kain, K.H. &amp; Klemke, R.L. Inhibition of cell migration by Abl family tyrosine kinases through uncoupling of Crk-CAS complexes. <i>J. Biol. Chem.</i> <b>19</b>, 16185&#150;16192 (2001).&nbsp;|&nbsp;<a href="http://dx.doi.org/10.1074%2Fjbc.M100095200" target="external">Article</a>&nbsp;|</li>
<li><A name="B19"></a>
Frasca, F., Vigneri, P., Vella, V., Vigneri, R. &amp; Wang, J.Y. Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to Hepatocyte Growth Factor. <i>Oncogene</i> <b>20</b>, 3845&#150;3856 (2001).&nbsp;|&nbsp;<a href="/doifinder/10.1038%2Fsj.onc.1204531" target="external">Article</a>&nbsp;|&nbsp;<a href="http://links.isiglobalnet2.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=Nature&SrcApp=Nature&DestLinkType=FullRecord&KeyUT=000169494700010&DestApp=WOS_CPL" target="external">ISI</a>&nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DC%2BD3MXlt1KrsLo%3D&pissn=1465-7392&pyear=2003&md5=d36c83f8cc1534a2eb6c1ff357ad55c9" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B20"></a>
Zukerberg, L.R. <i>et al</i>. Cables links Cdk5 and c-Abl and facilitates Cdk5 tyrosine phosphorylation, kinase upregulation, and neurite outgrowth. <i>Neuron</i> <b>26</b>, 633&#150;646 (2000).&nbsp;|&nbsp;<a 
href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=npg&cmd=Retrieve&db=PubMed&list_uids=10896159&dopt=Abstract" target="external"><span 
class="intlink">PubMed</span></a> &nbsp;|&nbsp;<a href="http://links.isiglobalnet2.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=Nature&SrcApp=Nature&DestLinkType=FullRecord&KeyUT=000087991600014&DestApp=WOS_CPL" target="external">ISI</a>&nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DC%2BD3cXkvVOlu7Y%3D&pissn=1465-7392&pyear=2003&md5=6db6afaefab6238d9cf5fece73d52c86" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B21"></a>
Woodring, P.J., Hunter, T. &amp; Wang, J.Y.J. Inhibition of c-Abl tyrosine kinase activity by filamentous actin. <i>J. Biol. Chem.</i> <b>276</b>, 27104&#150;27110 (2001).&nbsp;|&nbsp;<a href="http://dx.doi.org/10.1074%2Fjbc.M100559200" target="external">Article</a>&nbsp;|&nbsp;<a 
href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=npg&cmd=Retrieve&db=PubMed&list_uids=11309382&dopt=Abstract" target="external"><span 
class="intlink">PubMed</span></a> &nbsp;|&nbsp;<a href="http://links.isiglobalnet2.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=Nature&SrcApp=Nature&DestLinkType=FullRecord&KeyUT=000169966900051&DestApp=WOS_CPL" target="external">ISI</a>&nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DC%2BD3MXlsV2jtbw%3D&pissn=1465-7392&pyear=2003&md5=903900fd20ba324f08a789d35a89366e" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B22"></a>
Diakonova, M. <i>et al</i>. Epidermal growth factor induces rapid and transient association of phospholipase C-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 with EGF-receptor and filamentous actin at membrane ruffles of A431 cells. <i>J. Cell Sci.</i> <b>108</b>, 2499&#150;2509 (1995).&nbsp;|&nbsp;<a 
href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=npg&cmd=Retrieve&db=PubMed&list_uids=7673364&dopt=Abstract" target="external"><span 
class="intlink">PubMed</span></a> &nbsp;|&nbsp;<a href="http://links.isiglobalnet2.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=Nature&SrcApp=Nature&DestLinkType=FullRecord&KeyUT=A1995RF82800037&DestApp=WOS_CPL" target="external">ISI</a>&nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DyaK2MXmsFOns7k%3D&pissn=1465-7392&pyear=2003&md5=c25476c55e9945a021cde84217dfe1c5" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B23"></a>
DeMali, K.A. &amp; Kazlauskas, A. Activation of Src family members is not required for the platelet-derived growth factor B receptor to initiate mitogenesis. <i>Mol. Cell Biol.</i> <b>18</b>, 2014&#150;2022 (1998).&nbsp;|&nbsp;<a 
href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=npg&cmd=Retrieve&db=PubMed&list_uids=9528773&dopt=Abstract" target="external"><span 
class="intlink">PubMed</span></a> &nbsp;|&nbsp;<a href="http://links.isiglobalnet2.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=Nature&SrcApp=Nature&DestLinkType=FullRecord&KeyUT=000072613700026&DestApp=WOS_CPL" target="external">ISI</a>&nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DyaK1cXitFeqt7w%3D&pissn=1465-7392&pyear=2003&md5=622d277da12a67978fa53ee8b3627b1a" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B24"></a>
Ji, Q., Ermini, S., Baulida, J., Sun, F. &amp; Carpenter, G. Epidermal growth factor signaling and mitogenesis in <i>Plcg1</i> null mouse embryonic fibroblasts. <i>Mol. Biol. Cell</i> <b>9</b>, 749&#150;757 (1997).&nbsp;|&nbsp;<a href="http://links.isiglobalnet2.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=Nature&SrcApp=Nature&DestLinkType=FullRecord&KeyUT=000073739700004&DestApp=WOS_CPL" target="external">ISI</a>&nbsp;|</li>
<li><A name="B25"></a>
Smith, M.R. <i>et al</i>. Phospholipase C-gamma 1 can induce DNA synthesis by a mechanism independent of its lipase activity. <i>Proc. Natl Acad. Sci. USA</i> <b>91</b>, 6554&#150;6558 (1994).&nbsp;|&nbsp;<a 
href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=npg&cmd=Retrieve&db=PubMed&list_uids=8022819&dopt=Abstract" target="external"><span 
class="intlink">PubMed</span></a> &nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DyaK2cXlslKjsbs%3D&pissn=1465-7392&pyear=2003&md5=7ee18d3dc057a3611f7b85866f63724e" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B26"></a>
Stolz, L.E., Kuo, W.J., Longchamps, J., Sekhon, M. &amp; York, J.D. INP51, a yeast inositol polyphosphate Inp54 required for phosphatidylinositol 4,5-bisphosphate homeostasis and whose absence confers a cold-resistant phenotype. <i>J. Biol. Chem.</i> <b>19</b>, 11852&#150;11860 (1998).&nbsp;|&nbsp;<a href="http://dx.doi.org/10.1074%2Fjbc.273.19.11852" target="external">Article</a>&nbsp;|</li>
<li><A name="B27"></a>
Raucher, D. <i>et al</i>. Phosphatylinositol 4,5-bisphosphate functions as a second messenger that regulates cytoskeleton-plasma membrane adhesion. <i>Cell</i> <b>100</b>, 221&#150;228 (2000).&nbsp;|&nbsp;<a 
href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=npg&cmd=Retrieve&db=PubMed&list_uids=10660045&dopt=Abstract" target="external"><span 
class="intlink">PubMed</span></a> &nbsp;|&nbsp;<a href="http://links.isiglobalnet2.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=Nature&SrcApp=Nature&DestLinkType=FullRecord&KeyUT=000084932200006&DestApp=WOS_CPL" target="external">ISI</a>&nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DC%2BD3cXotFChsQ%3D%3D&pissn=1465-7392&pyear=2003&md5=3745e44b8c5fe31aa9c065a77e637938" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B28"></a>
Oh, E.S., Woods, A., Lim, S.T., Theibert, A.W. &amp; Couchman, J.R. Syndecan-4 proteoglycan cytoplasmic domain and phosphatidylinositol 4,5-bisphosphate coordinately regulate protein kinase C activity. <i>J. Biol. Chem.</i> <b>273</b>, 10624&#150;10629 (1998).&nbsp;|&nbsp;<a href="http://dx.doi.org/10.1074%2Fjbc.273.17.10624" target="external">Article</a>&nbsp;|&nbsp;<a 
href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=npg&cmd=Retrieve&db=PubMed&list_uids=9553124&dopt=Abstract" target="external"><span 
class="intlink">PubMed</span></a> &nbsp;|&nbsp;<a href="http://links.isiglobalnet2.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=Nature&SrcApp=Nature&DestLinkType=FullRecord&KeyUT=000073224200073&DestApp=WOS_CPL" target="external">ISI</a>&nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DyaK1cXivFKnu74%3D&pissn=1465-7392&pyear=2003&md5=de1d6c37fcfa0ab27046d85de289ff37" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B29"></a>
Ronnstrand, L. <i>et al</i>. Overactivation of phospholipase C-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 renders platelet-derived growth factor <img border=0 src="/__chars/beta/black/med/base/glyph.gif" align="middle" alt="beta">-receptor expressing cells independent of the phosphatidylinositol 3-kinase pathway for chemotaxis. <i>J. Biol. Chem.</i> <b>274</b>, 22089&#150;22094 (1999).&nbsp;|&nbsp;<a href="http://dx.doi.org/10.1074%2Fjbc.274.31.22089" target="external">Article</a>&nbsp;|&nbsp;<a 
href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=npg&cmd=Retrieve&db=PubMed&list_uids=10419537&dopt=Abstract" target="external"><span 
class="intlink">PubMed</span></a> &nbsp;|&nbsp;<a href="http://links.isiglobalnet2.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=Nature&SrcApp=Nature&DestLinkType=FullRecord&KeyUT=000081721100090&DestApp=WOS_CPL" target="external">ISI</a>&nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DyaK1MXltVymuro%3D&pissn=1465-7392&pyear=2003&md5=2e951c6d7c0bdbff69ccf2bbea70f9fc" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B30"></a>
Pendergast, A.M. <i>et al</i>. Evidence for regulation of the human Abl tyrosine kinase by a cellular inhibitor. <i>Proc. Natl Acad. Sci. USA</i> <b>88</b>, 5927&#150;5931 (1991).&nbsp;|&nbsp;<a 
href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=npg&cmd=Retrieve&db=PubMed&list_uids=1712111&dopt=Abstract" target="external"><span 
class="intlink">PubMed</span></a> &nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DyaK3MXkvV2lu78%3D&pissn=1465-7392&pyear=2003&md5=876c05ca390d0d514c1c665e6bf8771f" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B31"></a>
Ivan, M. <i>et al</i>. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. <i>Science</i> <b>20</b>, 464&#150;9 (2001).</li>
<li><A name="B32"></a>
Goga, A. <i>et al</i>. Oncogenic activation of c-Abl by mutation within its last exon. <i>Mol. Cell Biol.</i> <b>13</b>, 4967&#150;4975 (1993).&nbsp;|&nbsp;<a 
href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=npg&cmd=Retrieve&db=PubMed&list_uids=8336729&dopt=Abstract" target="external"><span 
class="intlink">PubMed</span></a> &nbsp;|&nbsp;<a href="http://links.isiglobalnet2.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=Nature&SrcApp=Nature&DestLinkType=FullRecord&KeyUT=A1993LN40500052&DestApp=WOS_CPL" target="external">ISI</a>&nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DyaK3sXlslymtrw%3D&pissn=1465-7392&pyear=2003&md5=3f8019a0591cbfe3fed1a816495b2134" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B33"></a>
Furstoss, O. <i>et al</i>. c-Abl is an effector of Src for growth factor-induced c-<i>myc</i> expression and DNA synthesis. <i>EMBO J.</i> <b>21</b>, 514&#150;524 (2002).&nbsp;|&nbsp;<a href="http://dx.doi.org/10.1093%2Femboj%2F21.4.514" target="external">Article</a>&nbsp;|&nbsp;<a href="http://links.isiglobalnet2.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=Nature&SrcApp=Nature&DestLinkType=FullRecord&KeyUT=000174014700004&DestApp=WOS_CPL" target="external">ISI</a>&nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DC%2BD38XhvFGrtbY%3D&pissn=1465-7392&pyear=2003&md5=420a9a30ce36f2289b80bbb7e00cf247" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B34"></a>
Mayer, B. &amp; Baltimore, D. Mutagenic analysis of the roles of SH2 and SH3 domains in regulation of the Abl tyrosine kinase. <i>Mol. Cell Biol.</i> <b>14</b>, 2883&#150;2894 (1994).&nbsp;|&nbsp;<a 
href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=npg&cmd=Retrieve&db=PubMed&list_uids=8164650&dopt=Abstract" target="external"><span 
class="intlink">PubMed</span></a> &nbsp;|&nbsp;<a href="http://links.isiglobalnet2.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=Nature&SrcApp=Nature&DestLinkType=FullRecord&KeyUT=A1994NG75600005&DestApp=WOS_CPL" target="external">ISI</a>&nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DyaK2cXkslOisbs%3D&pissn=1465-7392&pyear=2003&md5=3b37b1f13851e8f7dd405914948913ee" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B35"></a>
Brasher, B.B. &amp; Van Etten, R.A. c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. <i>J. Biol. Chem.</i> <b>275</b>, 35631&#150;35637 (2000).&nbsp;|&nbsp;<a href="http://dx.doi.org/10.1074%2Fjbc.M005401200" target="external">Article</a>&nbsp;|&nbsp;<a 
href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=npg&cmd=Retrieve&db=PubMed&list_uids=10964922&dopt=Abstract" target="external"><span 
class="intlink">PubMed</span></a> &nbsp;|&nbsp;<a href="http://links.isiglobalnet2.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=Nature&SrcApp=Nature&DestLinkType=FullRecord&KeyUT=000165422800106&DestApp=WOS_CPL" target="external">ISI</a>&nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DC%2BD3cXotFehs74%3D&pissn=1465-7392&pyear=2003&md5=ef49879c06d118c507cf2971f9f083e9" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B36"></a>
Van Etten, R.A. Cycling, stressed-out and nervous: cellular functions of c-Abl. <i>Trends Cell Biol.</i> <b>9</b>, 179&#150;186 (1999).&nbsp;|&nbsp;<a href="http://dx.doi.org/10.1016%2FS0962-8924%2899%2901549-4" target="external">Article</a>&nbsp;|&nbsp;<a 
href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=npg&cmd=Retrieve&db=PubMed&list_uids=10322452&dopt=Abstract" target="external"><span 
class="intlink">PubMed</span></a> &nbsp;|&nbsp;<a href="http://links.isiglobalnet2.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=Nature&SrcApp=Nature&DestLinkType=FullRecord&KeyUT=000081758500004&DestApp=WOS_CPL" target="external">ISI</a>&nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DyaK1MXjtV2hsLg%3D&pissn=1465-7392&pyear=2003&md5=ab955ebb21d291b37b6245d62e31702b" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B37"></a>
Barila, D. &amp; Superti-Furga, G. An intramolecular SH3-domain interaction regulates c-Abl activity. <i>Nature Genet.</i> <b>18</b>, 280&#150;282 (1998).&nbsp;|&nbsp;<a 
href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=npg&cmd=Retrieve&db=PubMed&list_uids=9500553&dopt=Abstract" target="external"><span 
class="intlink">PubMed</span></a> &nbsp;|&nbsp;<a href="http://links.isiglobalnet2.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=Nature&SrcApp=Nature&DestLinkType=FullRecord&KeyUT=000072325000029&DestApp=WOS_CPL" target="external">ISI</a>&nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DyaK1cXhtlKruro%3D&pissn=1465-7392&pyear=2003&md5=a284093522842ca79b12a2ebba768d8d" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B38"></a>
Jackson, P. &amp; Baltimore, D. N-terminal mutations activate the leukemogenic potential of the myristoylated form of c-Abl. <i>EMBO J.</i> <b>8</b>, 449&#150;456 (1989).&nbsp;|&nbsp;<a 
href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=npg&cmd=Retrieve&db=PubMed&list_uids=2542016&dopt=Abstract" target="external"><span 
class="intlink">PubMed</span></a> &nbsp;|&nbsp;<a href="http://links.isiglobalnet2.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=Nature&SrcApp=Nature&DestLinkType=FullRecord&KeyUT=A1989T348700016&DestApp=WOS_CPL" target="external">ISI</a>&nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DyaL1MXhvFSiur4%3D&pissn=1465-7392&pyear=2003&md5=daf5033472adcffcfe4fe050507e2543" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B39"></a>
Pluk, H., Dorey, K. &amp; Superti-Furga, G. Autoinhibition of c-Abl. <i>Cell</i> <b>108</b>, 247&#150;259 (2002).&nbsp;|&nbsp;<a 
href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=npg&cmd=Retrieve&db=PubMed&list_uids=11832214&dopt=Abstract" target="external"><span 
class="intlink">PubMed</span></a> &nbsp;|&nbsp;<a href="http://links.isiglobalnet2.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=Nature&SrcApp=Nature&DestLinkType=FullRecord&KeyUT=000173521300011&DestApp=WOS_CPL" target="external">ISI</a>&nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DC%2BD38XhtV2hsbs%3D&pissn=1465-7392&pyear=2003&md5=ad06777ed338b7dc95c45852a3016eda" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B40"></a>
Cong, F. <i>et al</i>. Cytoskeletal protein PSTPIP1 directs the PEST-type protein tyrosine phosphatase to the c-Abl kinase to mediate Abl dephosphorylation. <i>Mol. Cell</i> <b>6</b>, 1413&#150;1423 (2000).&nbsp;|&nbsp;<a 
href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=npg&cmd=Retrieve&db=PubMed&list_uids=11163214&dopt=Abstract" target="external"><span 
class="intlink">PubMed</span></a> &nbsp;|&nbsp;<a href="http://links.isiglobalnet2.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=Nature&SrcApp=Nature&DestLinkType=FullRecord&KeyUT=000166239500013&DestApp=WOS_CPL" target="external">ISI</a>&nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DC%2BD3MXlvFagsA%3D%3D&pissn=1465-7392&pyear=2003&md5=4f28c2a1b094f1131c00cef4d7fcb9e1" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B41"></a>
Echarri, A. &amp; Pendergast, A.M. Activated c-Abl is degraded by the ubiquitin-dependent proteasome pathway. <i>Curr. Biol.</i> <b>11</b>, 1759&#150;1765 (2001).&nbsp;|&nbsp;<a href="http://dx.doi.org/10.1016%2FS0960-9822%2801%2900538-3" target="external">Article</a>&nbsp;|&nbsp;<a 
href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=npg&cmd=Retrieve&db=PubMed&list_uids=11719217&dopt=Abstract" target="external"><span 
class="intlink">PubMed</span></a> &nbsp;|&nbsp;<a href="http://links.isiglobalnet2.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=Nature&SrcApp=Nature&DestLinkType=FullRecord&KeyUT=000172363400021&DestApp=WOS_CPL" target="external">ISI</a>&nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DC%2BD3MXos1Klsrg%3D&pissn=1465-7392&pyear=2003&md5=76b20bc1a771bd740a167a65308e25bb" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B42"></a>
Gallo, G. &amp; Letourneau, P.C. Axon guidance: A balance of signals sets axons on the right track. <i>Curr. Biol.</i> <b>9</b>, R490&#150;R492 (1999).&nbsp;|&nbsp;<a href="http://dx.doi.org/10.1016%2FS0960-9822%2899%2980304-2" target="external">Article</a>&nbsp;|&nbsp;<a 
href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=npg&cmd=Retrieve&db=PubMed&list_uids=10395535&dopt=Abstract" target="external"><span 
class="intlink">PubMed</span></a> &nbsp;|&nbsp;<a href="http://links.isiglobalnet2.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=Nature&SrcApp=Nature&DestLinkType=FullRecord&KeyUT=000081234500013&DestApp=WOS_CPL" target="external">ISI</a>&nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DyaK1MXktlOqt7o%3D&pissn=1465-7392&pyear=2003&md5=20e6defb3b59da362a2f2fc1e0d73927" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B43"></a>
Osborne, S.L., Meunier, F.A. &amp; Schiavo, G. Phosphoinositides as key regulators of synaptic function. <i>Neuron</i> <b>32</b>, 9&#150;12 (2001).&nbsp;|&nbsp;<a 
href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=npg&cmd=Retrieve&db=PubMed&list_uids=11604134&dopt=Abstract" target="external"><span 
class="intlink">PubMed</span></a> &nbsp;|&nbsp;<a href="http://links.isiglobalnet2.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=Nature&SrcApp=Nature&DestLinkType=FullRecord&KeyUT=000171525200004&DestApp=WOS_CPL" target="external">ISI</a>&nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DC%2BD3MXnsl2ks74%3D&pissn=1465-7392&pyear=2003&md5=848fa2ba651db09a372c13e76618f5c2" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B44"></a>
Irvin, B.J., Williams, B.L., Nilson, A.E., Maynor, H.O. &amp; Abraham, R.T. Pleiotropic contributions of phospholipase C-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 (PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1) to T-cell antigen receptor-mediated signaling: reconstitution studies of a PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1-deficient Jurkat T-cell line. <i>Mol. Cell Biol.</i> <b>20</b>, 9149&#150;9161 (2000).&nbsp;|&nbsp;<a href="http://dx.doi.org/10.1128%2FMCB.20.24.9149-9161.2000" target="external">Article</a>&nbsp;|&nbsp;<a 
href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=npg&cmd=Retrieve&db=PubMed&list_uids=11094067&dopt=Abstract" target="external"><span 
class="intlink">PubMed</span></a> &nbsp;|&nbsp;<a href="http://links.isiglobalnet2.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=Nature&SrcApp=Nature&DestLinkType=FullRecord&KeyUT=000168366100006&DestApp=WOS_CPL" target="external">ISI</a>&nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DC%2BD3MXivVamurY%3D&pissn=1465-7392&pyear=2003&md5=435dc3d5675b0f742aba82274805417e" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B45"></a>
Valius, M., Bazenet, C. &amp; Kazlauskas, A. Tyrosines 1021 and 1009 are phosphorylation sites in the carboxy terminus of the platelet-derived growth factor receptor beta subunit and are required for binding of phospholipase C gamma and a 64-kilodalton protein, respectively. <i>Mol. Cell Biol.</i> <b>13</b>, 133&#150;143 (1993).&nbsp;|&nbsp;<a 
href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?holding=npg&cmd=Retrieve&db=PubMed&list_uids=7678051&dopt=Abstract" target="external"><span 
class="intlink">PubMed</span></a> &nbsp;|&nbsp;<a href="http://links.isiglobalnet2.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=Nature&SrcApp=Nature&DestLinkType=FullRecord&KeyUT=A1993KD78500016&DestApp=WOS_CPL" target="external">ISI</a>&nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DyaK3sXntlOqtA%3D%3D&pissn=1465-7392&pyear=2003&md5=8408abb941392d04f06b871db253fe25" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li>
<li><A name="B46"></a>
Williams, B.L. <i>et al</i>. Phosphorylation of Tyr319 in ZAP-70 is required for T-cell antigen receptor-dependent phospholipase C-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 and Ras activation. <i>EMBO J.</i> <b>18</b>, 1832&#150;1844 (1999).&nbsp;|&nbsp;<a href="http://dx.doi.org/10.1093%2Femboj%2F18.7.1832" target="external">Article</a>&nbsp;|&nbsp;<a href="http://links.isiglobalnet2.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=Nature&SrcApp=Nature&DestLinkType=FullRecord&KeyUT=000079658300012&DestApp=WOS_CPL" target="external">ISI</a>&nbsp;|&nbsp;<a href="http://chemport.cas.org/cgi-bin/sdcgi?APP=ftslink&action=reflink&origin=npg&version=1.0&coi=1:CAS:528:DyaK1MXivVyksrs%3D&pissn=1465-7392&pyear=2003&md5=002667fcbd965c163886e831a467b377" target="external" alt="Chemical 
Abstracts Service">ChemPort</a>&nbsp;|</li></ol><table xmlns="" cellpadding="0" cellspacing="0" border="0" width="470"><tr><td rowspan="2" height="20"><img alt="" height="20" width="1" src="/images/spacer.gif"></td><td align="right"><img alt="" height="3" width="5" src="/ncb/images/arrow_black_up.gif">&nbsp;<a class="top" href="#top">Top</a></td></tr><tr><td height="7" align="right"><img alt="" height="7" width="1" src="/images/spacer.gif"></td></tr><tr><td colspan="2" height="1"><img alt="" height="1" width="470" src="/ncb/images/spacer_grey.gif"></td></tr><tr><td colspan="2" height="20"><img alt="" height="20" width="1" src="/images/spacer.gif"></td></tr></table><a xmlns="" name="Acknowledgments"></a><span xmlns="" class="heading3">Acknowledgments</span><br xmlns=""><span xmlns="" class="articletext">This work was supported by NIH grants CA70940 and GM62375 to A.M.P., NIH training grant CA09111-25 to R.P., National Institute of Health grant GM47286 to R.T.A., Howard Hughes Medical Institute funding to J. T. Y, and funded in part by GlaxoSmithKline. We thank G. Carpenter (Vanderbilt University, Nashville, TN) for the PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 null fibroblasts, R.Van Etten (Harvard Medical School, Boston, MA) for c-Abl constructs, T. Pawson (Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Canada) for GST&#150;PLC-<img border=0 src="/__chars/gamma/black/med/base/glyph.gif" align="middle" alt="gamma">1 fusion proteins, and A. Koleske (Yale University, New Haven, CT) for Abl/Arg null MEFs. We thank S. Finn and P. Zipfel (Duke University) for critically reading the manuscript, J. Stevensen-Paulik and A. Seeds (Duke University) for help in running the HPLC, and M. Calera (Harvard Medical School) for the PAE/PDGFR-<img border=0 src="/__chars/beta/black/med/base/glyph.gif" align="middle" alt="beta"> cell line.</span><br xmlns=""><br xmlns=""><p xmlns="" class="articletext"><b>Competing interests statement:</b>&nbsp;
The authors declare that they have no competing financial interests.</p></td></tr></table></td><td width="15"><img alt="" height="1" width="15" src="/images/spacer.gif"/></td><td valign="top" width="130"><table xmlns="" cellpadding="0" cellspacing="0" border="0" width="130"><tr><td><img alt="" height="34" width="1" src="/images/spacer.gif"></td></tr><tr><td colspan="2" height="22"><img alt="" height="22" width="1" src="/images/spacer.gif"></td></tr><tr><td colspan="2" class="whitesml" height="20" bgcolor="#546D9F" align="center"><b>FULL  TEXT</b></td></tr><tr><td valign="middle" colspan="2" bgcolor="#DFE9FD" height="17" align="center" class="blacksml2"><table cellpadding="1" cellspacing="0" border="0" width="106"><tr><td width="3"><img border="0" alt="" height="5" width="3" src="/ncb/images/arrow_black_prev.gif"></td><td width="100" align="center"><a class="breadcrumblink" href="/cgi-taf/DynaPage.taf?file=/ncb/journal/v5/n4/full/ncb948.html">Previous</a><a class="breadcrumblink" href="/cgi-taf/DynaPage.taf?file=/ncb/journal/v5/n4/full/ncb950.html"> | Next</a></td><td height="10" width="3"><img alt="" height="5" width="3" src="/ncb/images/arrow_black.gif"></td></tr></table></td></tr><tr><td colspan="2"><img alt="" height="1" width="130" src="/ni/images/spacer.gif"></td></tr><tr><td width="15" bgcolor="#DFE9FD" height="15" align="center" class="blacksml2"><img alt="" border="0" height="5" width="3" src="/ncb/images/arrow_black.gif"></td><td width="115" bgcolor="#DFE9FD" height="17" class="blacksml2"><a class="breadcrumblink" href="/cgi-taf/DynaPage.taf?file=/ncb/journal/v5/n4/index.html">Table of contents</a></td></tr><tr><td colspan="2" height="15" align="center" class="blacksml2"><table cellpadding="1" cellspacing="0" border="0" width="130"><tr><td bgcolor="#DFE9FD"><table cellpadding="0" cellspacing="0" border="0" width="128"><tr><td colspan="2" align="center" bgcolor="#FFFFFF"><img alt="" height="5" width="1" src="/images/spacer.gif"></td></tr><tr><td width="23" align="center" bgcolor="#FFFFFF"><img alt="Download PDF" height="14" width="14" src="/ncb/images/icon_pdf.gif"></td><td height="14" width="105" bgcolor="#FFFFFF"><a class="breadcrumblink" href="/cgi-taf/DynaPage.taf?file=/ncb/journal/v5/n4/full/ncb949.html&filetype=pdf">Download PDF</a></td></tr><tr><td valign="middle" colspan="2" align="center" bgcolor="#FFFFFF"><img alt="" height="6" width="1" src="/images/spacer.gif"></td></tr><tr><td valign="middle" width="23" align="center" bgcolor="#FFFFFF"><img alt="Send to a friend" height="10" width="13" src="/ncb/images/icon_email.gif"></td><td valign="middle" height="12" width="105" bgcolor="#FFFFFF"><a class="breadcrumblink" onclick="mailafriend('0','/ncb/sendfriend/sendfriend_form.html','600','600')" href="javascript:void(0)">Send 
to a friend</a></td></tr><tr><td valign="middle" colspan="2" align="center" bgcolor="#FFFFFF"><img alt="" height="5" width="1" src="/ni/images/spacer.gif"></td></tr></table></td></tr></table></td></tr><table cellpadding="0" cellspacing="0" border="0" width="130"><tr><td height="10"><img alt="" height="1" width="15" src="/ni/images/spacer.gif"></td><td height="10"><img alt="" height="1" width="115" src="/ni/images/spacer.gif"></td></tr><tr><td align="center" width="15" class="blacksml2"><img alt="" border="0" height="3" width="5" src="/ncb/images/arrow_black_dwn.gif"></td><td height="15" width="115" class="blacksml2"><a class="breadcrumblink" href="#abstract">Abstract</a></td></tr><tr><td align="center" width="15" class="blacksml2"><img alt="" border="0" height="3" width="5" src="/ncb/images/arrow_black_dwn.gif"></td><td height="15" width="115" class="blacksml2"><a class="breadcrumblink" href="#Results">Results</a></td></tr><tr><td align="center" width="15" class="blacksml2"><img alt="" border="0" height="3" width="5" src="/ncb/images/arrow_black_dwn.gif"></td><td height="15" width="115" class="blacksml2"><a class="breadcrumblink" href="#Discussion">Discussion</a></td></tr><tr><td align="center" width="15" class="blacksml2"><img alt="" border="0" height="3" width="5" src="/ncb/images/arrow_black_dwn.gif"></td><td height="15" width="115" class="blacksml2"><a class="breadcrumblink" href="#Methods">Methods</a></td></tr><tr><td align="center" width="15" class="blacksml2" valign="top"><img alt="" vspace="4" border="0" height="5" width="3" src="/ncb/images/arrow_black.gif"></td><td height="15" width="115" class="blacksml2"><a class="breadcrumblink" href="javascript:void(0)" onClick="window.open('/ncb/journal/v5/n4/fig_tab/ncb949_ft.html','fig_tab','width=600,height=400,scrollbars=yes')">Figures &amp; Tables</a></td></tr><tr><td align="center" width="15" class="blacksml2"><img alt="" border="0" height="3" width="5" src="/ncb/images/arrow_black_dwn.gif"></td><td height="15" width="115" class="blacksml2"><a class="breadcrumblink" href="#Acknowledgments">Acknowledgments</a></td></tr><tr><td align="center" width="15" class="blacksml2"><img alt="" border="0" height="3" width="5" src="/ncb/images/arrow_black_dwn.gif"></td><td height="15" width="115" class="blacksml2"><a class="breadcrumblink" href="#References">References</a></td></tr><tr><td align="center" colspan="2" class="blacksml2"><img alt="" height="5" width="1" src="/images/spacer.gif"></td></tr><tr><td align="center" colspan="2" class="blacksml2"><img alt="" height="1" width="130" src="/ncb/images/spacer_grey.gif"></td></tr><tr><td class="blacksml2" width="15" align="center"><img src="/images/arrow_black.gif" width="3" height="5" border="0" alt=""></td><td class="blacksml2" width="115" height="15"><a href="/ncb/journal/v5/n4/ris/ncb949.ris" target="_blank" class="breadcrumblink">Export citation</a></td></tr><tr><td class="blacksml2" width="15" align="center"><img src="/images/arrow_black.gif" width="3" height="5" border="0" alt=""></td><td class="blacksml2" width="115" height="15"><a href="/ncb/journal/v5/n4/ris/ncb949refs.ris" target="_blank" class="breadcrumblink">Export references</a></td></tr><tr><td align="center" colspan="2" class="blacksml2"><img alt="" height="5" width="1" src="/images/spacer.gif"></td></tr>
 <SCRIPT>
 var show = '556';
 if(show > 0)
 {
 document.write('<tr>');
 document.write('<td class="blacksml2" width="15" align="center">');
 document.write('<img src="/ncb/images/arrow_black.gif" width="3" height="5" border="0" alt="">');
 document.write('</td>');
 document.write('<td class="blacksml2" width="115" height="15">');
 }
 </SCRIPT>
       <A class="breadcrumblink" HREF="javascript:void(0)" onclick="window.open('http://sherman.nature.com/arls/Query?prod=NCB&query=http%3A//www.nature.com/doifinder/10.1038/ncb949&type=AF&src_title=A%20new%20link%20between%20the%20c-Abl%20tyrosine%20kinase%20and%20phosphoinositide%20signalling%20through%20PLC-%26gamma%3B1&src_jrnl=Nature%20Cell%20Biology&src_vol=5&src_pp=309-319&src_date=2003&target=popup', 'autonomypopup', 'resizeable=yes,scrollbars=yes,scrolling=yes,statusbar=no,navbar=no,width=550,height=550');return false;">More articles like this</A>
   <SCRIPT>
	if(show > 0){
	   document.write('</td>');
	   document.write('</tr>');
	   document.write('<tr>');
	   document.write('<td height="5" align="center" colspan="2" class="blacksml2"><img alt="" height="5" width="1" src="/nsmb/images/spacer.gif"></td>');
	   document.write('</tr>');
	   document.write('<tr>');
	   document.write('<td align="center" colspan="2" class="blacksml2"><img alt="" height="1" width="130" src="/ncb/images/spacer_grey.gif"></td>');
	   document.write('</tr>');

	}
   </SCRIPT><table cellpadding="0" cellspacing="0" border="0" width="100%"><tr><td height="30" align="center">&nbsp;</td></tr><tr><td align="center"><span class="greysml">ADVERTISEMENT</span></td></tr><tr><td><img alt="" height="3" width="1" src="/ni/images/spacer.gif"></td></tr><tr><td align="center"><script type="text/javascript" language="javascript">
<!--
document.write ('<ILAYER HEIGHT="600" WIDTH="120" VISIBILITY="hidden" ID="layer2"></ILAYER>');
document.write ('<NOLAYER>');
document.write ('<IFRAME scrolling="no" frameborder="0" vspace="0" hspace="0" marginheight="0" marginwidth="0" height="600" width="120" SRC="http://ad.doubleclick.net/adi/cellbio.nature.com/curr_back;pos=right;' + adinf + ';sz=120x600;ord=' + ordval + '?">');
document.write ('<A HREF="http://ad.doubleclick.net/jump/cellbio.nature.com/curr_back;pos=right;abr=!ie4;abr=!ie5;' + adinf + 'sz=120x600;ord=' + ordval + '?"></A>');
document.write ('<IMG alt="advertisement" align="center" HSPACE="0" HEIGHT="600" WIDTH="120" BORDER="0" SRC="http://ad.doubleclick.net/ad/cellbio.nature.com/curr_back;pos=right;abr=!ie4;abr=!ie5;' + adinf + 'sz=120x600;ord=' + ordval + '?"></IFRAME>');
document.write ('</NOLAYER>');
// --></script><noscript><a href="http://ad.doubleclick.net/jump/cellbio.nature.com/curr_back;pos=right;abr=!NN2;sz=120x600;ord=07893195?"><img alt="advertisement" height="600" width="120" border="0" src="http://ad.doubleclick.net/ad/cellbio.nature.com/curr_back;pos=right;abr=!NN2;sz=120x600;ord=07893195?"></a></noscript></td></tr></table></table></table></td></tr></table></td></tr></table><table cellpadding="0" cellspacing="0" border="0" width="100%"><tr><td align="center">&nbsp;</td></tr><tr><td height="4" align="center" bgcolor="#546D9F"><img alt="" height="4" width="1" src="/images/spacer.gif"></td></tr><tr><td align="center"><table cellpadding="0" cellspacing="0" border="0" width="760"><tr><td colspan="2" valign="top"><img alt="" height="10" width="1" src="/images/spacer.gif"></td></tr><tr><td width="145" valign="top"><a href="/ncb/"><img height="41" width="128" border="0" alt="Nature Cell Biology" src="/includes/rj_globnavimages/ncb_footer_logo.gif"></a><br><span class="blacksmltext">
ISSN:&nbsp;1465-7392<br>
EISSN:&nbsp;1476-4679</span></td><td class="blacknorm" width="615" valign="top"><a class="footer" href="/ncb/index.html">Journal home</a> | <a class="footer" href="/cgi-taf/DynaPage.taf?file=/ncb/journal/vaop/ncurrent/index.html">Advance online publication</a> | <a class="footer" href="/cgi-taf/DynaPage.taf?file=/ncb/journal/v6/n3/index.html">
Current issue
</a> | <a class="footer" href="/cgi-taf/DynaPage.taf?file=/ncb/archive/index.html">Archive</a> | <a class="footer" href="/ncb/press_release/index.html">Press releases</a> | 
<a class="footer" href="/ncb/supplements/index.html">Supplements</a> | <a class="footer" href="/ncb/webfocus/index.html">Focuses</a> | <a class="footer" href="/ncb/image/index.html">Cell of the month</a> | 
<a class="footer" href="/ncb/authors/index.html">For authors</a> | <a class="footer" href="http://mts-ncb.nature.com" target="_blank">Online submission</a> | <a class="footer" href="http://npg.nature.com/npg/servlet/Content?data=xml/01_reprints.xml&amp;style=xml/01_reprints.xsl" target="_blank">Permissions</a> | <a class="footer" href="/ncb/referees/index.html">For referees</a> | <a class="footer" href="/cgi-taf/DynaPage.taf?file=/ncb/journal/v6/n1/index.html">Free online issue</a> | <a class="footer" href="/ncb/about/index.html">About the journal</a> | <a class="footer" href="/ncb/contact/index.html">Contact the journal</a> | <a class="footer" href="/registration/index.taf?site_source=ncb" target="_blank">Subscribe</a> | <a class="footer" href="http://advertising.nature.com" target="_blank">Advertising</a> | <a class="footer" href="http://npg.nature.com/npg/forms/03_current.jsp">work@npg</a> | <a class="footer" href="http://www.naturereprints.com" target="_blank">naturereprints</a> | <a class="footer" href="/ncb/site/index.html">About this site</a> | <a class="footer" href="http://npg.nature.com/npg/servlet/Content?data=xml/07_home.xml&amp;style=xml/07_home.xsl" target="_blank">For librarians</a>
</td></tr><tr><td colspan="2" valign="top"><img alt="" height="10" width="1" src="/images/spacer.gif"></td></tr></table></td></tr><tr><td height="2" align="center" bgcolor="#546D9F"><img alt="" height="2" width="1" src="/images/spacer.gif"></td></tr><tr><td align="center"><table xmlns="" cellpadding="0" cellspacing="0" border="0" width="760"><tr><td colspan="3" valign="top"><img alt="" height="10" width="1" src="/includes/rj_globnavimages/spacer.gif"></td></tr><tr><td align="right" width="130" valign="top"><a href="http://npg.nature.com/npg/servlet/Content?data=xml/02_welcome.xml&style=xml/02_welcome.xsl"><img border="0" alt="Nature Publishing Group, publisher of Nature, and other science journals and reference works" height="26" width="26" src="/includes/rj_globnavimages/npg_footer_logo.gif"></a></td><td align="right" width="15" valign="top"><img alt="" height="1" width="15" src="/includes/rj_globnavimages/spacer.gif"></td><td class="blacksmltext" width="615" valign="middle"><a href="/copyright/copyright_ncb.html" onClick="window.open('/copyright/copyright_ncb.html','copyright_window','toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=no,resizable=no,copyhistory=yes,width=450,height=280,top=380,left=20');return false;" class="copyright">&copy;2003&nbsp;Nature Publishing Group</a> | <a target="_blank" class="privacy" href="http://npg.nature.com/npg/servlet/Content?data=xml/08_privacy.xml&style=xml/08_privacy.xsl">Privacy policy</a></td></tr><tr><td colspan="3" valign="top"><img alt="" height="10" width="1" src="/includes/rj_globnavimages/spacer.gif"></td></tr></table></td></tr></table><script type="text/javascript" language="javascript">
<!--
document.writeln ('<layer src="http://ad.doubleclick.net/adl/cellbio.nature.com/curr_back;pos=top;dcopt=ist;' + adinf + 'sz=468x60;ord=' + ordval + '?" visibility="hidden" width="468" height="60" onload="moveToAbsolute(layer1.pageX,layer1.pageY);clip.height=60;clip.width=468;visibility=\'show\';"></layer>');
// -->
</script><script type="text/javascript" language="javascript">
<!--
document.writeln ('<layer SRC="http://ad.doubleclick.net/adl/cellbio.nature.com/curr_back;pos=right;' + adinf + 'sz=120x600;ord=' + ordval + '?" visibility="hidden"  width="120" height="600" onload="moveToAbsolute(layer2.pageX,layer2.pageY);clip.height=600;clip.width=120;visibility=\'show\';"></layer>');
// -->
</script></body></html>